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ABSTRACT 
Background: Multiple sclerosis (MS) is the most common chronic inflammatory and 
neurodegenerative autoimmune disease of the central nervous system. The cause of 
MS remains unknown, but both genetic and environmental predisposing factors have 
been identified. Vitamin D deficiency, smoking and Epstein-Barr virus (EBV) 
infection are the most prominent identified environmental risk factors for MS, but how 
early before MS onset these risk factors have impact is not known. EBV infection, 
smoking and vitamin D deficiency are risk factors also associated with cancer. The 
risk of cancer among Finnish MS patients has not been studied since 1990s.  
Aims of the study: Finnish Maternity Cohort (FMC) is a serum bank collected 
from Finnish pregnant women since 1983. The main aims of this thesis were to study 
whether maternal smoking and vitamin D status during pregnancy are associated 
with later risk of MS among Finnish women, and to study whether maternal EBV 
antibodies affect the MS risk of the mother and her offspring. Further aims were to 
investigate the safety and efficacy of vitamin D supplementation in combination with 
fingolimod therapy in MS patients, and to study cancer risk and factors affecting it 
among MS patients in Southwest Finland from January 2004 to December 2012.   
Results: Vitamin D deficiency during pregnancy was associated with an almost 
2-fold risk of MS in both the Finnish mothers and their offspring. Smoking Finnish 
mothers had a 45% higher future MS risk compared to non-smokers. Highest titers 
of maternal EBV antibodies in comparison with the lowest tripled the MS risk in the 
mother and doubled it in her offspring independently of vitamin D and cotinine 
levels. Use of vitamin D supplements as an add-on to fingolimod showed beneficial 
effects on magnetic resonance image (MRI) outcomes and depression. Risk of cancer 
among MS patients in Southwest Finland was equal to controls, but age at breast 
cancer diagnosis was significantly higher among the MS patients. Smoking history 
of the patients was incompletely documented. 
Conclusions: Correcting for vitamin D deficiency during pregnancy can be 
beneficial in MS prevention for both the mother and her child. Smoking is a risk 
factor for MS in Finnish women and should be a target for lifestyle intervention in 
young women. Prevention of EBV infection by vaccination could hold potential for 
decreasing the risk of both numerous cancers and MS, but the risk of increasing MS 
predisposition by postponing the timing of the EBV infection is a potential risk that 
must be taken into consideration. 
Keywords: Multiple sclerosis, pregnancy, vitamin D, EBV infection, smoking, cancer 
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TIIVISTELMÄ 
Taustaa: Pesäkekovettumatauti eli multippeliskleroosi (MS) on yleisin krooninen 
tulehduksellinen ja rappeuttava keskushermoston autoimmuunisairaus. Sen 
aiheuttaja on tuntematon, mutta useita altistavia geneettisiä ja ympäristötekijöitä on 
tunnistettu. D-vitamiinin puutos, tupakointi ja Epstein-Barr virus- (EBV) infektio 
ovat merkittävimmät ympäristöriskitekijät, mutta sitä kuinka varhain nämä 
riskitekijät vaikuttavat ei tunneta. Tupakointi ja EBV-infektio ovat riskitekijöitä 
paitsi MS-tautiin myös syöpään sairastumiseen. Suomalaisten MS-potilaiden 
syöpäriskiä ei ole tutkittu 1990-luvun jälkeen.  
Tavoitteet: Väitöskirjatyön keskeisenä tavoitteena oli tutkia, onko suomalaisten 
äitien raskaudenaikaisella tupakoinnilla ja matalalla D-vitamiinipitoisuudella yhteys 
äidin ja lapsen myöhempään riskiin sairastua MS-tautiin, ja onko äidin EBV vasta-
aineilla vaikutusta äidin ja lapsen myöhempään MS-riskiin. Lisäksi väitöskirjassa 
tutkittiin D-vitamiinilisän tehoa ja turvallisuutta MS-potilailla yhdistettynä 
fingolimodihoitoon ja selvitettiin MS-potilaiden syöpäriski Varsinais-Suomessa 
tammikuun 2004 ja joulukuun 2012 välisenä ajanjaksona.  
Tulokset: Äidin raskaudenaikainen D-vitamiinipuutos kaksinkertaisti 
suomalaisen äitiyskohortin naisten ja raskauksista syntyneiden lasten riskin sairastua 
MS-tautiin. Äidin EBV vasta-aineet lisäsivät MS taudin riskiä kolminkertaiseksi 
naisilla ja 2.5-kertaiseksi heidän jälkeläisillään riippumatta seerumin D-vitamiini- ja 
kotiniinitasoista. Kohortin tupakoivien suomalaisten naisten riski sairastua MS 
tautiin tulevaisuudessa oli 45% korkeampi kuin tupakoimattomilla. D-vitamiinilisä 
fingolimodia käyttävillä MS potilailla oli turvallista ja sillä oli suotuisa vaikutus 
magneettikuvauksella todettaviin MS-tautimuutoksiin ja depressioon kahden 
vuoden seurannassa. Varsinais-Suomen MS potilaiden syöpäriski ei eronnut 
sairaanhoitopiirin kontrolliväestön syöpäriskistä, mutta MS-tautia sairastavilla 
rintasyöpä todettiin merkitsevästi myöhemmällä iällä kuin verrokeilla. Tupa-
kointitausta oli puutteellisesti dokumentoitu. 
Johtopäätökset: Raskaudenaikaisen D-vitamiinipuutoksen korjaamisesta 
saattaa olla hyötyä MS taudin ehkäisemisessä niin äideillä kuin heidän jälke-
läisillään. Tupakointi on MS taudin riskitekijä myös suomalaisilla naisilla ja 
tupakoinnin ennaltaehkäisy tulisi olla keskeinen interventio nuorilla naisilla. EBV-
infektion ennaltaehkäisy rokotteella saattaisi suojata MS taudilta, mutta EBV 
infektion lykkääntyminen rokotteella saattaisi jopa lisätä MS riskiä. 
Avainsanat: MS-tauti, raskaus, D-vitamiini, EBV-infektio, tupakointi, syöpä  
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Abbreviations 
25(OH)D 25-hydroxyvitamin D  
Ab Antibody 
AE Adverse event 
ARR Annual relapse rate 
BBB Blood-brain barrier 
BC Breast cancer 
BMI Body mass index 
CI Confidence interval 
CIS Clinically isolated syndrome 
CMV Cytomegalovirus 
CNS Central nervous system 
CSF Cerebrospinal fluid 
DIS Dissemination in space 
DIT Dissemination in time 
DMT Disease modifying therapy 
EA-D Early antigen, diffuse  
EA-R Early antigen, restricted  
EBNA Epstein-Barr virus nuclear antigen 
EBV Epstein-Barr virus 
EDSS Expanded disability status scale 
EP Evoked potential 
FMC Finnish maternity cohort 
FTY720 Fingolimod 
GA Glatiramer acetate 
Gd Gadolinium 
HHV-4 Human herpesvirus 4  
HLA Human leucocyte antigen 
ICD International Classification of Diseases 
IFN Interferon 
IgG Immunoglobulin G 
IL Interleukin 
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IM Infectious mononucleosis 
IS Immunosuppressant 
MHC Major histocompatibility complex 
MOG Myelin oligodendrocyte glycoprotein 
MRI Magnetic resonance imaging 
MS Multiple sclerosis 
NEDA No evidence of disease activity 
NF  Neurofilament 
NK Natural killer 
OCB Oligoclonal bands 
OCT Optic coherence tomography 
ON Optic neuritis 
OR Odds ratio 
POMS Pediatric onset MS 
PPMS Primary progressive multiple sclerosis 
PBVC Percentage brain volume change 
RCT Randomized controlled trial 
RR Risk ratio 
RIS Radiologically isolated syndrome 
RRMS Relapsing remitting multiple sclerosis 
SHS Secondhand smoking 
SPMS Secondary progressive multiple sclerosis 
UV Ultraviolet 
UVB Ultraviolet B 
UVR Ultraviolet radiation 
VDR Vitamin D receptor 
VCA Viral capsid antigen  
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1 Introduction 
Multiple sclerosis (MS) is the most common chronic, inflammatory, demyelinating 
and neurodegenerative autoimmune disease affecting the central nervous system 
(CNS) in young adults. It is a leading cause of disability, early retirement and 
socioeconomic burden (Rotstein et al., 2006; Fromont et al., 2014; Hollenbach and 
Oksenberg, 2015; Filippi et al., 2018). Women are affected more commonly than 
men and a steady global increase in MS incidence and prevalence in females has 
been observed in recent years (Koch-Henriksen and Sørensen, 2010; Trojano et al., 
2012; Sumelahti et al., 2014; Leray et al., 2016; Filippi et al., 2018; Magyari and 
Sorensen, 2019). The rapidly increased female predominance of MS may reflect a 
possible role of environmental risk factors mainly affecting women (Orton et al., 
2006; Koch-Henriksen and Sørensen, 2010). Several studies support the presence of 
a clear genetic component, whereas the relatively low concordance among 
monozygotic (MZ) twins and an increasing concordance in Finnish dizygotic (DZ) 
twins during the past two decades indicate that environmental factors also play a 
central role in the increasing prevalence and risk of developing MS (Särkijärvi et al., 
2006; Kuusisto et al., 2008; Hedström et al., 2009). The cause of MS remains 
unknown, but a generally accepted hypothesis is that it is a predominantly immune-
mediated inflammatory and neurodegenerative disease and is likely to be a product 
of complex associations between genetic susceptibility, infectious risk factors and 
environmental exposures (Leray et al., 2016; Sospedra and Martin, 2016). Some of 
the most pertinent environmental factors consistently associated with an increased 
risk of developing MS are previous Epstein-Barr virus (EBV) infection, vitamin D 
deficiency, smoking and adolescent obesity (Hedström et al., 2009; Leray et al., 
2016; Olsson, Barcellos and Alfredsson, 2016; Filippi et al., 2018).  Whether a 
potential future vaccine or antiviral treatment of EBV would be beneficial in MS 
prevention, or whether a vaccine with partial efficacy potentially leading to later 
timing of the primary EBV infection could in a worst case scenario indeed increase 
the MS risk are not known. Although the epidemiological evidence supporting the 
role of vitamin D deficiency as a risk factor for developing MS is comprehensive 
(Munger et al., 2006), the optimal timing of vitamin D supplement initiation for MS 
susceptible subjects or to the general population is not known. Determining whether 
Kira Åkerlund 
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this would ultimately lead to a reduction in MS occurrence would require decades of 
follow-up and taking into account changes in other known and unknown 
predisposing factors. Although the disease biomarkers, clinical and paraclinical 
measurements (including imaging) and MS treatments have evolved such that it is 
possible in most cases to stop the inflammatory phase, there is still no cure for MS. 
The highest unmet therapeutic need is the treatment of progressive disease and 
restoration of CNS damage. Despite the challenges, the ultimate goal of MS research 
needs to be prevention through more effective identification and modification of 
lifestyle and environmental risk factors.  
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2 Review of the Literature 
2.1 Multiple sclerosis 
2.1.1 Clinical features 
MS has traditionally been classified largely based on its clinical characteristics into 
the phenotypes relapsing remitting (RRMS), secondary progressive (SPMS), 
primary progressive (PPMS) and progressive relapsing MS (PRMS) (Lublin and 
Reingold, 1996). Since the phenotypes are more complex and often clinically 
overlapping, refinements were proposed in 2013 in an attempt to add clinically 
relevant information to MS categorizations (Lublin et al., 2014). The reclassified 
categories are descriptive of the level of inflammatory activity observed compared 
to the degenerative progression of the disease and include the inactive clinically 
isolated syndrome (CIS), and if active, eventually RRMS. The designation of 
progressive MS disease comprises both the former PPMS (progressive accumulation 
of disability from onset) and SPMS (progressive accumulation of disability after 
initial relapsing course) phenotypes. Progressive MS can be divided into the 
subtypes active and with progression, active without progression, inactive with 
progression and inactive without progression. Activity is determined by clinical 
relapses or magnetic resonance imaging (MRI) activity (contrast-enhancing lesions; 
new and enlarging T2 lesions), whereas progression is mainly clinically evaluated 
(Lublin et al., 2014; Oh, Vidal-Jordana and Montalban, 2018). 
In a majority of the MS population (∼80-85%), the disease starts with an acute 
relapse and succeeds with a relapsing remitting course. RRMS is characterized by 
acute exacerbations and remissions during the early focal inflammation phase, 
followed by progression due to neurodegeneration (Weinshenker, Issa and 
Baskerville, 1996; Leray et al., 2010; Confavreux and Vukusic, 2014). A relapse is 
considered to be a clinically expressed acute, focal or multifocal inflammation and 
demyelination in the CNS, characterized by occurrence, recurrence or worsening of 
neurological symptoms during at least 24 hours (Youl et al., 1991; McDonald et al., 
2001).  
The majority of RRMS cases eventually convert to SPMS over time (after 
approximately 10-20 years in untreated MS patients), defined by a steady disease 
Kira Åkerlund 
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progression and disability accumulation (Confavreux, Aimard and Devic, 1980; 
WEINSHENKER et al., 1989; Debouverie et al., 2009; Tedeholm et al., 2015). The 
median time to SPMS conversion has been about 19 years in several large studies 
(Tremlett et al., 2008; Rzepiński et al., 2019), whereas it is less clear when RRMS 
patients convert to SPMS in the modern treatment era (Oh, Vidal-Jordana and 
Montalban, 2018).  
PPMS affects ∼10-15% of the MS population and is characterized by 
neurodegeneration leading to disease progression and accumulated disability 
(Confavreux and Vukusic, 2014).  
Pediatric onset MS (POMS) affects <10% of the MS population and is defined 
as MS debuted in childhood (<15-18-year-old subjects). In Finland, child cases are 
considered pediatric when <16 years old. 95-100% of all POMS are classified as 
RRMS. Progression to SPMS is slower than in the adult MS population (Boiko et 
al., 2002; Krupp, Banwell and Tenembaum, 2007; Bar-or, 2008; Krupp et al., 2013; 
Waldman et al., 2014; Alroughani and Boyko, 2018). 
If the criteria of MS are not readily met, the first relapse event is referred to as a 
CIS, which most often is monosymptomatic, and usually affects the optic nerve, 
spinal cord or brainstem. The overall probability of developing MS after an attack of 
optic neuritis (ON) is 50% in 15 years (Brodsky et al., 2008). The risk of developing 
MS increases if there are paramedical findings of cerebrospinal fluid (CSF) 
oligoclonality or at least one clinically silent white matter lesion in the MRI (Brex et 
al., 2002; Tintoré et al., 2006, 2008; Fisniku et al., 2008).  
In 2009, Okuda et al introduced a formal description of the radiologically 
isolated syndrome (RIS), based on observations of incidental MRI findings 
suggestive of demyelinating disease in persons without typical clinical MS 
presentations (Okuda et al., 2009). Later study observations suggest that a significant 
proportion of RIS cases have cognitive impairment similar to that seen in part of the 
MS population and approximately two-thirds of RIS cases develop radiological 
progression and 30-45% develop either acute or progressive neurological symptoms 
during a mean follow-up time of five years (Granberg et al., 2013; Okuda et al., 
2014).  
Life expectancy among MS patients is reduced by ∼10 years compared to the 
general population and mortality is almost 3-fold higher than in the general 
population (Sumelahti et al., 2010; E Kingwell et al., 2012; Lunde et al., 2017). 
Patients older at MS onset or with PPMS have shorter survival (E Kingwell et al., 
2012; Scalfari, Knappertz, et al., 2013). In about 50% of the MS population, MS is 
the cause of death (Sumelahti et al., 2010). Infection and suicide rates are higher 
(Scalfari, Knappertz, et al., 2013) and excess mortality rates from accidents and other 
comorbidities, except from cancer (Brønnum-Hansen, Koch-Henriksen and 
Stenager, 2004; Koch-Henriksen et al., 2017), are higher than among the general 
Review of the Literature 
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population (Brønnum-Hansen, Koch-Henriksen and Stenager, 2004; Burkill et al., 
2017; Lunde et al., 2017; Pirttisalo et al., 2018). Stroke was observed to decrease 
the survival rate among MS patients in a population-based Finnish Northern 
Ostrobothnia cohort and infections in Southwest Finland (Krökki et al., 2014; 
Murtonen et al., 2018), whereas mortality from cancers in the MS population of 
higher age was increased in Finland (Sumelahti et al., 2002).  
2.1.2 Epidemiology 
Approximately 2.3 million people have MS worldwide (Multiple Sclerosis 
International Federation, 2013), over 700,000 individuals in Europe (European 
Multiple Sclerosis Platform, 2013; Multiple Sclerosis International Federation, 
2013; Browne et al., 2014; Gitto, 2017), and the worldwide prevalence varies with 
geography and ethnicity (Pugliatti, Sotgiu and Rosati, 2002; Kingwell et al., 2013). 
The disease is associated with a high economic burden of ∼14.6 billion euros within 
Europe in 2010 (Gustavsson et al., 2011). MS onset usually occurs at an age ranging 
from 20 to 40 years. The incidence and prevalence of the MS population are 
increasing globally with a female-to-male predominance of 2-3:1 (Bentzen et al., 
2010; Koch-Henriksen, Magyari and Laursen, 2015; Howard, Trevick and Younger, 
2016; Leray et al., 2016; Amato et al., 2018; Filippi et al., 2018; Magyari and 
Sorensen, 2019). 
The epidemiological hallmark of MS is an uneven geographic distribution. The 
incidence and prevalence of MS vary significantly between countries, with a global 
median prevalence of 33 per 100,000 people (Sumelahti et al., 2000, 2003; Tienari 
et al., 2004; Simpson et al., 2011, 2019; Trojano et al., 2012; Oh, Vidal-Jordana and 
Montalban, 2018). In North America and Europe the prevalence rates are high 
(>100/100,000), whereas prevalence levels are low in Eastern Asia and Sub-Saharan 
Africa (2/100,000) (Leray et al., 2016). A higher global risk of MS has been strongly 
associated with latitude, with an increasing MS occurrence following a longitudinal 
south-north gradient in northern parts of the globe and a north-south gradient in 
southern part of the world, and with a minimal prevalence at the equator (Alonso and 
Hernán, 2008; Koch-Henriksen and Sørensen, 2010; Simpson et al., 2011, 2019).  
A high-risk focus for MS in Scandinavia, Finland included, was identified in the 
1960s (Kurtzke, 1968, 1974). Finland is a high-risk region for MS with large regional 
epidemiological differences, and prevalence varies from 100 to over 200 per 100,000 
inhabitants in different areas (Sumelahti et al., 2001, 2003; Sarasoja et al., 2004; 
Tienari et al., 2004; Krökki et al., 2011; Holmberg et al., 2013). National MS 
prevalence in Finland has not been studied, but an estimate of 10,000 to 11,000 
patients at the end of 2018 has been presented based on Finnish MS register data 
(Laakso et al., 2019). The female-to-male ratio in RRMS in western Finland has 
Kira Åkerlund 
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increased from 2.2 to 2.7 since the 1990s and at the same time, the mean age of the 
MS population has increased from less than 40 years to over 50 years (Holmberg et 
al., 2013; Sumelahti et al., 2014; Pirttisalo, Soilu-Hänninen and Sipilä, 2019). The 
east-west gradient was recently confirmed by showing an age-standardized 
prevalence to European standard population of 280/100,000 in Southwest Finland 
versus 168/100,000 in North Karelia and an annual age-standardized incidence (5-
year period from 2012 to 2016) of 12.1/100,000 versus 8.6/100,000 respectively 
(Pirttisalo, Soilu-Hänninen and Sipilä, 2019).  
The prevalence of MS reported from other Nordic countries is also increasing. 
In Norway, MS prevalence was 208/100,000 inhabitants on December 31, 2013. This 
observation was based on the Norwegian Patient Registry, although without the 
evidence of a latitude gradient that had been observed in previous studies. The 
increase in Norwegian MS prevalence was speculated to have several causes, 
including improved and more accessible neurological health care services and 
diagnostics, with possible contributions of environmental risk factors such as 
smoking and vitamin D and changes in lifestyle behavior along with an increased 
survival in MS (Berg-Hansen et al., 2014, 2015; Grytten, Torkildsen and Myhr, 
2015). Similar factors may contribute to the prevalence changes observed in other 
Nordic countries. 
In Sweden, nationwide prevalence on December 31, 2008, was 189/100,000 and 
significantly increased with increasing north latitude for both males and females. 
Incidence had increased to an average of 10.2/100,000 (Ahlgren, Odén and Lycke, 
2014). In 2008, immigrants constituted 14% of the Swedish population. Prevalence 
increased in migrants from countries with a lower MS risk, and among Iranian 
migrants to a prevalence rate exceeding that in the general population, suggesting a 
genetic risk altered by changed environmental-lifestyle MS risk factors (Ahlgren et 
al., 2010; Ahlgren, Odén and Lycke, 2011, 2012).   
In Denmark, MS prevalence and incidence have been continuously updated with 
accumulated data from the Danish Multiple Sclerosis Registry established in 1956. 
Standardized prevalence increased to 232/100,000 inhabitants in 2013 (Bentzen et 
al., 2010; Koch-Henriksen, Magyari and Laursen, 2015). Similar to other Nordic 
countries, MS prevalence in Iceland is 166.5/100,000 inhabitants (Elíasdóttir, 
Kjartansson and Olafsson, 2018). 
The pooled prevalence of familial MS (FMS), defined as MS cases with at least 
one family member in the first, second, third degree or other relatives of probands 
that are affected by MS, has been calculated at 12.6% of the global total MS 
population, with a significant heterogeneity independent of latitude or ethnicity, that 
highlight the accumulation effects of genetics and environmental factors (Harirchian 
et al., 2018). 
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2.1.3 Diagnosis and follow-up 
2.1.3.1 Diagnostic criteria 
There is no single specific test for MS, be it lab-based or otherwise, due to the 
unknown etiology and specific pathogenesis of the disease (Deisenhammer et al., 
2019). Diagnosis is based on the demonstration of dissemination of focal 
neurological deficits in space (DIS) and time (DIT), as well as exclusion of 
differential diagnoses (Aktas et al., 2018). The first clinical diagnostic criteria for 
MS were established in 1965 (Schumacher et al., 1965). Poser et al later added 
paraclinical evidence and laboratory findings to the diagnostic criteria of definite 
(Table 1) and probable MS in the 1980s (Poser et al., 1983). 
Table 1.  Diagnostic criteria for multiple sclerosis by Poser et al., modified from Poser et al. 1983 
Category Attacks 
Clinical 
evidence 
Paraclinical 
evidence 
CSF  
OCB/IgG 
Clinically definite     
1. CDMS A1 2 2   
2. CDMS A2        2 1 and 1  
Laboratory supported     
1. LSDMS B1 2 1 or  1 + 
2. LSDMS B2 1 2  + 
3. LSDMS B3 1 1 and 1 + 
OCB/IgG = oligoclonal bands or increased immunoglobulin G (IgG) specific to the cerebrospinal 
fluid (CSF). Paraclinical evidence of central nervous system (CNS) lesions = findings elicited by 
hyperthermia, evoked potential studies, computed tomography (CT) and nuclear magnetic 
resonance (NMR) scans or special urological studies. CDMS = clinically definite MS, LSDMS = 
laboratory supported definite MS. Modified table printed with permission (Poser et al., 1983). 
The McDonald diagnostic criteria for MS were issued in 2001 by the International 
Panel on the Diagnosis of Multiple Sclerosis (McDonald et al., 2001) and have since 
been updated in 2005, 2010 and 2017 to facilitate diagnostic accuracy and exclusion 
of differential diagnoses. Diagnosis is made based on clinical and/or paraclinical (i.e. 
imaging and laboratory) findings of disseminated CNS lesions attributable to MS 
(Polman et al., 2005; Brownlee et al., 2017; Thompson et al., 2018). The Barkhof-
Tintore MRI criteria were used to demonstrate DIS in the two first versions and 
replaced by simplified MRI criteria for DIT contrived by Swanton et al in 2010, 
enabling diagnosis of MS based on a single MRI in some CIS patients (Swanton et 
al., 2006). Revisions of MRI criteria for the diagnosis of MS proposed by the 
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European Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) network 
were incorporated in the 2017 revision (Rovira et al., 2015; Filippi et al., 2016). 
Laboratory findings of cerebrospinal fluid (CSF)-specific oligoclonal bands 
(OCBs) were used as part of MS criteria in the 2001 and 2005 McDonald revisions, 
but were excluded in the 2010 revision. They were again included in the 2017 
McDonald criteria, since CSF-specific OCBs in numerous studies were shown to be 
an independent predictor of the risk of a second attack in adult patients with a CIS 
(Thompson et al., 2018). 
CIS is defined as an episode of a symptom or symptoms attributable to a debut 
of MS, that lasts for 24 hours up to one month, but that does not yet meet the 2017 
McDonald criteria for definite MS. Clinical evidence of at least one symptom 
episode attributable to focal CNS demyelination is compulsory for CIS and MS 
diagnosis. MRI of the CNS can demonstrate further DIS by one or more T2-
hyperintense lesions (symptomatic or asymptomatic) that are characteristic for MS 
in two or more of four CNS areas: periventricular, cortical or juxtacortical, 
infratentorial brain regions and the spinal cord. MRI can confirm DIT by the 
simultaneous presence of gadolinium (Gd)-enhancing T1 lesions and non-enhancing 
lesions at any time or by a new T2-hyperintense or Gd-enhancing lesion on follow-
up MRI, with reference to a baseline scan (Thompson et al., 2018).  
The Radiologically Isolated Syndrome Consortium presented their first 
retrospective cohort in 2014 with an observed five-year conversion rate to the first 
clinical event of 34% among RIS patients (mean age at RIS diagnosis of 37.2 years). 
Cervical lesions are central predictors of clinical conversion from RIS to CIS or MS 
(Granberg et al., 2013; Lebrun, 2015), and infratentorial, spinal cord involvement 
and the total number of lesions are more relevant predictors of progression than Gd 
enhancement (Maia Jr. et al., 2012; Okuda et al., 2014). 
Diagnosis of PPMS requires one year of disease progression independent of 
clinical relapse and two of the three following criteria must be met: A) One or more 
(symptomatic or asymptomatic) T2-hyperintense lesions characteristic of multiple 
sclerosis in at least one of the following brain regions: periventricular, cortical or 
juxtacortical, or infratentorial B) Two or more (symptomatic or asymptomatic) T2-
hyperintense lesions in the spinal cord and C) Presence of CSF-specific OCBs 
(Thompson et al., 2018). Definition of the time when RRMS converts to SPMS still 
poses a diagnostic challenge (Oh, Vidal-Jordana and Montalban, 2018). The 2017 
McDonald criteria for MS in patients with an attack at onset demonstrated by DIS 
and DIT are shown in table 2. 
For pediatric onset MS (POMS), many different diagnostic criteria have been 
proposed to meet the challenges of distinguishing MS from various acquired 
demyelinating syndromes that can occur in childhood. In most studies, the criteria 
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by the Pediatric International Study Group have been applied (Alroughani and 
Boyko, 2018). 
The differential diagnosis of neuromyelitis optica spectrum disorders (NMOSD) 
should be considered in any patient being evaluated for MS, since MS treatments 
can exacerbate NMOSDs (Kimbrough et al., 2012). Serological testing for 
antibodies to aquaporin 4 and myelin oligodendrocyte glycoprotein (MOG) should 
therefore be individually considered (Aktas et al., 2018; Thompson et al., 2018). 
Table 2.  The 2017 McDonald criteria for diagnosis of multiple sclerosis in patients with an attack 
at onset, modified from Thompson et al. 2018. 
 
Number of lesions with objective 
clinical evidence 
Additional data needed for a diagnosis of 
multiple sclerosis 
≥2 clinical 
attacks 
≥2 None* 
≥2 clinical 
attacks 
1 (as well as clear-cut historical 
evidence of a previous attack 
involving a lesion in a distinct 
anatomical location) 
None* 
≥2 clinical 
attacks 
1 Dissemination in space demonstrated by an 
additional clinical attack implicating a different 
CNS site or by MRI** 
1 clinical 
attack 
≥2 Dissemination in time demonstrated by an 
additional clinical attack or by MRI*** OR 
demonstration of CSF-specific oligoclonal 
bands**** 
1 clinical 
attack 
1 Dissemination in space demonstrated by an 
additional clinical attack implicating a different 
CNS site or by MRI**  
AND 
Dissemination in time demonstrated by an 
additional clinical attack or by MRI*** OR 
demonstration of CSF-specific oligoclonal 
bands**** 
*No additional tests are required to demonstrate DIS and DIT. However, if possible, all patients in 
whom the diagnosis of MS is being considered should obtain a brain MRI. Spinal cord MRI or CSF 
examination is recommended in patients with scarce or atypical clinical findings lacking paraclinical 
supportive evidence of MS. If imaging and paraclinical tests are negative, an alternative diagnosis 
should be considered. **At least one attack must be supported by objective findings. Clinical 
diagnosis based on objective clinical findings for two attacks is most secure. Reasonable evidence 
for another previous inflammatory demyelinating attack is sufficient for diagnosis, but caution is 
needed in the absence of residual objective evidence. *** The MRI criteria for DIS and DIT are 
described in the text above. **** The presence of CSF-specific OCBs does not demonstrate DIT 
per se but can substitute for the requirements for demonstration of this measurement (Thompson 
et al 2018). CIS = clinically isolated syndrome; MS = multiple sclerosis; DIS = dissemination in 
space; DIT = dissemination in time; MRI = magnetic resonance imaging; OCB = oligoclonal bands; 
CSF = cerebrospinal fluid; CNS = central nervous system. Modified table printed with permission 
(Thompson et al., 2018). 
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2.1.3.2 Follow-up 
2.1.3.2.1 Clinical outcome measures 
MS prognosis and intervention efficacy assessment are challenging, since the disease 
has a heterogenous nature that makes it difficult to capture disease activity and 
progression in a reliable, valid way. Many scorings reflecting the MS disease course 
have been introduced over time to meet the needs for objective and subjective 
evaluation tools in the clinic and for trial outcomes, for treatment and rehabilitation 
efficacy evaluation, and for assessment of the patients’ need for assistance or 
capacity to work (Elovaara et al., 2006). 
The traditionally used primary clinical outcome measures in MS phase 3 trials 
are the relapse rate and the Expanded Disability Status Scale (EDSS) (Uitdehaag, 
2014; van Munster and Uitdehaag, 2017). The American neurologist John Kurtzke 
created the Disability Status Scale (DSS) in the 1960s and later an expanded version 
(EDSS), as a method of qualifying MS disability. EDSS ranks the disease burden 
severity based on clinical symptoms on a scale from 0 (no clinical signs or subjective 
symptoms of MS in the neurological examination) to 10 (patient deceased) in 0.5-
unit increments. EDSS scoring covers assessment of the functional systems: visual, 
brainstem, pyramidal, cerebellar, sensory, bladder and bowel, and cerebral, as well 
as consideration of gait and walking distance ability with or without aids (Kurtzke, 
1983, 2015), and reflect fluctuations during relapses, remissions and disease 
progression useful in the evaluation of MS treatment efficacy (van Munster and 
Uitdehaag, 2017). Treatment of MS has been focused on reducing the number of 
relapses, regardless of the fact that the rate of relapses characteristic of RRMS shows 
no association with longtime disease prognosis (Confavreux and Vukusic, 2006; 
Scalfari, Neuhaus, et al., 2013). The annual relapse rate (ARR) is, however, still used 
as a primary outcome measure in most clinical phase 3 trials (Lim and 
Constantinescu, 2010; van Munster and Uitdehaag, 2017) although it is becoming 
overly restricted in the era of new and emerging potent disease modifying treatments 
(DMTs) for MS that have led to a shift in treatment expectations from one of partial 
response to one of potent remission.  
No evidence of disease activity (NEDA-3) has emerged as an outcome measure 
that consists of a composite of clinical relapses, EDSS disability and MRI outcomes 
(defined by the absence of clinical relapses, EDSS progression and radiological signs 
of disease, i.e. no new/enlarging T2 lesions or Gd-enhancing T1 lesions on MRI) 
(Rotstein, Healy, Malik, Chitnis, et al., 2015; Lu et al., 2017, 2018; Parks et al., 
2017).  
Today, national MS patient registries have become widely used and provide 
insight about key observations including disability progression rate, predictors of 
Review of the Literature 
 21 
increased disability, and changes in lifespan of the natural history of MS (Glaser et 
al., 2019). They provide a tool for treatment efficacy evaluation, both in MS research 
and clinics. Quality registers are valuable, as they provide data that cannot otherwise 
be captured, and particularly informative if multiple registries confirm similar 
findings that could also be utilized in conjunction with data from clinical trials to 
optimize treatment and improve long-term outcomes (Hurwitz, 2011a, 2011b; Koch-
Henriksen, Magyari and Laursen, 2015). In Finland, a national MS register was 
launched in 2014 (Laakso et al., 2019).  
2.1.3.2.2 Radiological outcome measures 
MRI technology and availability have improved since the 1990s and have become 
central in the diagnosis and follow-up of MS patients, possibly even contributing to 
the observations of increased MS prevalence in recent years by providing improved 
methods of case ascertainment (Howard, Trevick and Younger, 2016). In 2001, MRI 
was included in the MS diagnostic work-up recommendations of patients with CIS 
by an International Panel of experts, since it is more sensitive in detecting disease 
activity and new inflammatory lesions than clinical evaluation and monitoring of 
relapse numbers (McDonald et al., 2001). Guidelines for MRI use in MS diagnostics 
and follow-up have been modified since then and continue to be updated by the 
MAGNIMS, allowing both earlier, more accurate diagnosis and initiation of 
treatment (Filippi et al., 2016; Thompson et al., 2018).  
Relevant MRI findings are white matter focal lesions in the CNS, typical for MS 
in terms of distribution, morphology, evolution, and signal abnormalities on the 
following conventional MRI sequences; T2-weighted, T2-FLAIR (fluid attenuated 
inversion recovery) and T1-weighted scans before and after intravenous (IV) Gd 
contrast distribution (National Multiple Sclerosis Society, 2019). Gd enhancement 
is currently the reference standard to detect active inflammatory lesions in MS and 
demonstrates blood-brain barrier (BBB) breakdown in association with 
inflammation and demyelination. The disrupted BBB and glymphatic system allows 
the Gd molecule to traverse into the lesions where it can persist for two to three 
months and thus provide evidence of recent disease activity informative in MS 
treatment monitoring (Cotton et al., 2003; Iliff, Goldman and Nedergaard, 2015; 
Jessen et al., 2015; Saade et al., 2018; National Multiple Sclerosis Society, 2019). 
T2 lesions are unspecific but can be used to measure disease activity by providing 
information about serial imaging when active lesions (new or enlarging T2 lesions) 
are present between two scans (Simon, 2014). Radiologically, the burden of MS 
disease is measured by the total volume of T2 lesions, and MRI lesion load in early 
disease is a prominent prognostic factor for disease accumulation as well as a 
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predictor of RIS conversion to CIS and MS (Maia Jr. et al., 2012; Granberg et al., 
2013; Okuda et al., 2014; Lebrun, 2015; Rovira et al., 2015).  
A more suitable MRI measure of irreversible pathology in progressive MS is 
brain and gray matter atrophy, which reflects demyelination, axonal loss and gliosis 
(Fisher et al., 2008; Geurts et al., 2012; Rocca, Absinta and Filippi, 2012; Nandoskar 
et al., 2017). T1 hypointense lesions (“black holes”) reflect focal neurodegeneration 
when chronic and not enhancing and correlate with MS-related disability (Sahraian 
et al., 2010; Giorgio et al., 2014). Annualized percentage brain volume change 
(PBVC) as a measure of brain atrophy is also used in clinical trials as an outcome 
measure, since MS patients are shown to lose more brain volume per year (0.7% 
brain volume/year demonstrated for a group consisting of patients with first-
generation DMT or no treatment), well above rates associated with normal ageing 
(0.1-0.3% brain volume per year) (De Stefano et al., 2014; Vollmer et al., 2015).  
2.1.3.2.3 Biomarkers as outcome measures 
There is no specific test for MS due to the unknown etiology and specific 
pathogenesis of the disease (Deisenhammer et al., 2019). However, there are 
biomarkers that can be used as helpful tools in diagnosis, prediction and follow-up. 
A biomarker is an objective and quantifiable measurement that reflects the activity 
of a disease process (Strimbu and Tavel, 2010). According to Amur et al, there are 
four different types of biomarkers: diagnostic, prognostic, predictive and response 
biomarkers (Amur et al., 2015). Surrogate markers are defined as a subset of 
biomarkers characterized by specific criteria, making them suitable to use in trials as 
a substitute for a clinically meaningful endpoint as a direct measure of how a patient 
feels, functions or survives, and are expected to predict the effect of a therapy 
(Prentice, 1989; Hauser and Oksenberg, 2006).  
Potential serum and CSF biomarkers have not yet led to consensus on a marker 
that fulfills the criteria for surrogacy, although CSF-specific OCBs are a hallmark of 
MS-specific changes found in the majority of MS patients and implemented in the 
last revision of the McDonald 2017 criteria to demonstrate DIT (Nandoskar et al., 
2017; Thompson et al., 2018; Deisenhammer et al., 2019). OCBs strongly predict 
conversion from CIS to definite MS and increase the risk of a relapse 1.7-fold 
independently of baseline MRI (Tintoré et al., 2008; Dobson et al., 2013). Lack of 
OCBs has a high negative predictive value of 88% in lumbar puncture (LP) of CIS 
patients (Tintoré et al., 2001), indicating a red flag and consideration of alternative 
diagnoses in such patients during diagnostic work-up (Deisenhammer et al., 2019). 
Differences in MS disease mechanisms between OCB positive and negative MS 
subjects in Scandinavia (Norway, Sweden and Denmark) have been suggested 
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related to genetic differences based on genome-wide association studies (GWAS) 
(Mero et al., 2013). 
Neurofilaments (NF) are components of the neuronal cytoskeleton released in 
CSF in association with CNS damage, and are promising as future biomarkers for 
MS activity, progression, and treatment response (Cairns, Lee and Trojanowski, 
2004; Soelberg Sorensen and Sellebjerg, 2016; Varhaug et al., 2018, 2019; Bridel et 
al., 2019; Damasceno et al., 2019; Martin et al., 2019)(Teunissen and Khalil, 2012).  
Optic coherence tomography (OCT) is an optical form of ultrasound imaging 
that has shown potential as a noninvasive documentation biomarker for cell loss in 
the retinal nerve fiber layer through serial measurements correlating with disability, 
whole-brain and gray matter atrophy (Francis, 2013; Narayanan et al., 2014; Saidha 
et al., 2015; Garcia-Martin et al., 2017). OCT can be used to monitor macular edema 
in fingolimod-treated MS patients (Turaka and Bryan, 2012; Francis, 2013; Fragoso, 
2017; Fruschelli et al., 2019). 
2.1.3.2.4 Electrophysiological outcome measures 
The clinical use of function analyses by electro-neurophysiological measurements 
and evoked potentials (EPs) to confirm damage sites at different locations in the CNS 
has decreased in MS diagnostics (Paty et al., 1988; Polman et al., 2011; McGuigan, 
Fernández and Fernández, 2013). EPs, however, remain relevant, as they provide 
functional quantitative in vivo data on multimodal afferent and efferent pathways 
through cerebral and spinal long tracks and reveal subclinical lesions on the long 
sensory-motor pathways. Alteration of signal conduction is the main mechanism of 
signs and symptoms in MS, and multimodal EPs may thus serve as a representative 
measure of the functional impairment in the disease although they are insensitive to 
cerebellar, frontal and cognitive dysfunctions and have not yet been validated for 
evaluation of individual patients. Sensory EPs include brainstem auditory EP 
(BAEP, an auditive testing for abnormalities in hearing), visual EP (VEP) and 
somatosensory EP (SEP) (Hardmeier, Leocani and Fuhr, 2017). According to 
prospective and retrospective studies, EPs have good accuracy in monitoring and 
predicting short- and long-term functional evolution and disease progression and 
have a strong cross-correlation with EDSS (Kallmann et al., 2006; Invernizzi et al., 
2011; Margaritella et al., 2012; Ramanathan et al., 2013; Schlaeger, D’Souza, et al., 
2014; Schlaeger, Schindler, et al., 2014; Giffroy et al., 2017; Martinelli et al., 2017). 
In PPMS, VEP are abnormal in about 90% of the patients, adding diagnostic support 
(Leocani et al., 2006). SEP can be used to objectively confirm abnormalities by 
stimulating sensation tracts with electrical signals registered in an arm or a leg, 
whereas motor evoked potentials (MEP) can be applied to demonstrate motor 
dysfunction in the CNS.   
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2.1.4 Treatment 
2.1.4.1 Disease modifying therapies 
DMTs have been available since the first publication of interferon (IFN) effect on 
MS disease in the mid-1990s. Since then, several DMTs have been approved, 
including treatments with oral bioavailability and IV distribution (Niiranen and 
Remes, 2017; Trojano et al., 2017). The current DMTs reduce disease activity, seen 
as a reduction in ARR and MRI measures of disease burden, but their effect on 
disease progression and long-time disability accumulation is less clear (Wingerchuk 
and Weinshenker, 2016). 
In Finland, interferons (IFNs) became available in the mid-1990s, glatiramer 
acetate (GA) in 2004, natalizumab in 2006, fingolimod (FTY) available since 2011 
and reimbursed since 2012, alemtuzumab and teriflunomide (TRF) since 2013, 
dimethyl fumarate (DMF) since 2014 and cladribine since 2017. The current orally 
administered therapies include TRF, DMF, FTY and cladribine. Self-injectable 
therapies include IFN-beta, pegylated IFN, and GA. Monoclonal antibodies (Ab) 
natalizumab, alemtuzumab and ocrelizumab are administered IV (Multiple sclerosis: 
Current Care Guidelines Abstract, 2019). The chemotherapeutic agent mitoxantrone 
(MX) is rarely used due to the increased risk of malignancies and severe adverse 
events (SAEs), which are also consistently associated with the use of the traditional 
immunosuppressants (IS) azathioprine and cyclophosphamide (Achiron et al., 2005; 
Lebrun et al., 2008, 2011; Le Bouc et al., 2012; Kingwell et al., 2014; Wingerchuk 
and Weinshenker, 2016; Ragonese et al., 2017; Li et al., 2019). In the Finnish 
Current Care Guidelines for MS therapy, treatment initiation is guided by disease 
activity. MS is defined as active or highly active based on clinical relapses and MRI 
findings of new or enlarging T2 or Gd-enhancing lesions. Initiation of DMTs for RIS 
is still controversial and not recommended outside of clinical trials due to lack of 
beneficial evidence (Okuda et al., 2009; Granberg et al., 2013; Aktas et al., 2018).  
MS exacerbation treatment (mainly high-dose IV methyl prednisolone) has little 
or no effect on ARR or disease progression and is mainly aimed at alleviating 
relapses affecting mobility and function, including ON. Cessation of MS medication 
is recommended if there is no evidence of disease activity during 3 years of 
progression, and IFN-beta does not prevent permanent disability in SPMS (La 
Mantia et al., 2013; Multiple sclerosis: Current Care Guidelines Abstract, 2019). 
Pharmacological treatments in Finland for RRMS and PPMS are shown in table 3. 
Potential emerging immune modulating approaches (stem cells, DNA vaccines, 
nanoparticles, altered peptide ligands) for the treatment of MS, and therapeutic 
approaches for restoration of the damaged nervous system are also under 
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development (Dargahi et al., 2017). One of the most pressing unmet needs is the 
development of DMTs that slow disability accumulation in progressive forms of MS. 
Table 3.  Drug treatments for active and highly active RRMS and active PPMS in Finland  
MS type Treatment 
Active RRMS Dimethylfumarate 
Glatiramer acetate 
Interferon beta 
Ocrelizumab 
Teriflunomomide 
Highly active RRMS Alemtuzumab 
Cladribine 
Fingolimod 
Mitoxantrone 
Natalizumab 
Ocrelizumab 
Active PPMS Ocrelizumab 
Multiple sclerosis. Current Care Guidelines (referred September 7, 2019). www.kaypahoito.fi 
2.1.4.1.1 Fingolimod 
Fingolimod (FTY720, 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol) became 
the first Food and Drug Administration approved oral drug for MS treatment in 2010 
and has been available in Finland since 2011. It is an immunosuppressive drug 
derived from myriocin, a fungal metabolite that resembles sphingosine. Its 
mechanisms of action are related to binding four out of five sphingosine 1-
phosphatase (S1P) receptors (S1P1 in particular, as well as S1P3, S1P4 and S1P5), 
and act on the peripheral immune system through modulation of S1P receptors, 
leading to internalization and down-regulation of sphingosine 1-phosphate receptors, 
inhibition of S1P activity and sequestration of T-lymphocytes in the lymph nodes, 
thereby preventing the release of lymphocytes from lymph nodes and thus leading 
to a reduction in T-cell trafficking into the CNS (Mandala et al., 2002; Brinkmann, 
2007; Aktas et al., 2010). Interleukin-2 (IL-2) activated NK cells express S1P1,3,4,5, 
and it has been reported that S1P inhibits cell lysis of target cells including tumor 
cells and dendritic cells (DCs), an inhibitory activity reversed by FTY720 (Rolin et 
al., 2010). 
Efficacy of fingolimod treatment for RRMS has been demonstrated in 3 large 
Phase 3 clinical randomized controlled trials (RCT) ranging from 6 to 24 months, 
FREEDOMS I and II (FTY720 Research Evaluating Effects of Daily Oral Therapy 
in Multiple Sclerosis) and TRANSFORMS (Trial Assessing Injectable Interferon 
versus FTY720 Oral in Relapsing – Remitting Multiple Sclerosis) by showing 
decreased rates of relapse rates compared to placebo or weekly administered 
intramuscular interferon beta-1a, respectively. Compared to IFN-beta, fingolimod 
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(0.5mg daily orally administered) reduced relapse rates, MRI-activity (T2 and Gd-
enhancing lesions) and in the 2 placebo-controlled trials fingolimod additionally 
slowed disease progression (Kappos et al., 2006, 2010, 2015; Cohen et al., 2010; 
Calabresi et al., 2014; Sanford, 2014). Fingolimod also reduces brain volume loss 
compared to placebo but has safety issues warranting monitoring for infections, 
cancers, and certain transitory effects such as irregular cardiac function, decreased 
lymphocyte count and a higher level of liver enzymes (Guarnera, Bramanti and 
Mazzon, 2017). The drug is effective and relatively safe, with a well-described first-
dose side effect of bradycardia and atrioventricular block (generally asymptomatic) 
related to S1P receptors in the heart during its first hours of use. Other relatively 
rare potential AEs include infections (herpes simplex, herpes zoster, Cryptococcus, 
EBV, hepatitis, Molluscum contagiosum, and leishmaniosis), lung and thyroid 
complications, refractory headaches, encephalopathy, vasculopathy, tumefactive 
lesions in MRI and ophthalmological disorders (Sanford, 2014; Fragoso, 2017). In 
the TRANSFORMS trial, 0.5% of patients receiving fingolimod developed macular 
edema, with a higher risk of 20% among patients with diabetes or uveitis (Cohen et 
al., 2010). Therefore, a dilated fundus examination at baseline for diabetics and 
patients with a history of uveitis is recommended, and a 3- to 4-month follow-up 
macular OCT for MS patients undergoing fingolimod treatment (Lee, 2011; 
Multiple sclerosis: Current Care Guidelines Abstract, 2019). Overall, fingolimod 
did not show an increase in cancer risk in Phase 3 clinical trials (0.9% increase in 
fingolimod treated groups and 2.4% in placebo) (Kappos et al., 2014). The majority 
of reported cancers in FREEDOMS were skin cancers, including basal cell 
carcinoma, melanoma and Bowen´s disease. Also a few breast cancers (BC) were 
reported (Kappos et al., 2010; Calabresi et al., 2014; Guarnera, Bramanti and 
Mazzon, 2017). Fingolimod has demonstrated efficacy in multiple in vitro and in 
vivo cancer models, suggesting a potential therapeutic role in cancer patients. A 
possible anticancer mechanism is through the inhibition of sphingosine kinase 1, a 
proto-oncogene with in vitro and clinical cancer association, and anticancer 
properties may be attributable to actions on several other molecular targets (White 
et al., 2016).  
Second-generation sphingosine-1-phosphate receptor 1 modulators (siponimod, 
RCP-1063, ONO-4641, ponesimod) show promise in reducing some of the side 
effects associated with fingolimod (bradycardia, liver function abnormalities, and 
pulmonary fibrosis) (Cree, 2014). 
2.1.4.1.2 Vitamin D 
The role of vitamin D as a modulator of calcium and phosphorous and in bone 
formation and maintenance is well known, but vitamin D receptor (VDR) is also 
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expressed in multiple cells and most organs in the human body and is involved in 
immune modulation (Marino and Misra, 2019). 
Vitamin D is a prohormone and fat-soluble group of secosteroids available 
through diet, dietary supplementation and by the synthesis of cholecalciferol in the 
skin from cholesterol through a chemical reaction dependent on ultraviolet B (UVB) 
sun radiation (Holick et al., 1980; Calvo, Whiting and Barton, 2005; MacDonald, 
2019). Vitamin D3 (cholecalciferol, obtained from sunlight and diet) and D2 
(ergocalciferol, obtained from diet) are the most important vitamin D precursors for 
humans (Holick, 2006; F. Holick and Holick, 2010; Ross et al., 2011). Vitamin D 
action is expressed by the active vitamin D metabolite calcitriol (1,25-
dihydroxycholecalciferol). Calcitriol promotes increased intestinal absorption and 
regulation of serum calcium, magnesium and phosphate, and has a regulatory role in 
development and maintenance of bone health alongside with multiple other 
biological effects on cell growth and neuromuscular functions (Holick, 2004; 
Norman, 2008; Ross et al., 2011). The observation of VDR presence in human 
leucocytes paved the way for later discoveries of vitamin D immunomodulatory 
effects on immune functions and reduction of inflammation (Provvedini et al., 1983; 
Holick, 2004).  
 Vitamin D (represents D2 or D3, collectively known as calciferol) is 
biologically inactive and is converted into its active form by enzyme hydroxylation 
in the liver and kidneys. D3 is converted in the liver to calcifediol (25-
hydroxycholecalciferol) and D2 to 25-hydroxyergocalciferol. These two vitamin D 
metabolites are called 25-hydroxyvitamin D or 25(OH)D, which is the main 
circulating metabolite of vitamin D and measured from serum to determine a 
person´s vitamin D status (Hollis, 1996; DeLuca, 2004; Herrmann et al., 2017). 
Calcifediol is hydroxylated by the kidneys to calcitriol, which is the biologically 
active form of vitamin D. Of the human requirement for vitamin D, 80-90% is 
provided by production in the skin induced by UVB action (Holick et al., 2011; 
Wacker and Holick, 2013). Food provides only about 100 IU of vitamin D daily, and 
if fortified approximately 300-400 IU per day (Pierrot-Deseilligny and Souberbielle, 
2017). Recommendations on target 25(OH)D serum levels vary across authorities 
(US labs generally report levels in ng/mL, other countries in nmol/L. 1 ng/mL equals 
∼2.5 nmol/L). The toxic levels of vitamin D, potentially generating hypercalcemia, 
appear to be located largely above serum levels of 375 nmol/L, corresponding to a 
daily intake much higher than 10,000 IU (Hathcock et al., 2007). A review from 
2014 concluded that the most beneficial serum levels of 25(OH)D for all outcomes 
is approximately 75 nmol/mL, although there is controversy due to differences 
between ethnic groups (Bischoff-Ferrari, 2014).  
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2.1.4.1.3 Role of vitamin D supplementation in MS 
Vitamin D has been promoted for use in several non-skeletal diseases (including MS, 
cancer, type 1 diabetes) because of its immunomodulatory, anti-inflammatory, 
antioxidant and anti-fibrotic actions (Jamka et al., 2015; Murdaca et al., 2019). In 
the majority of MS patients, vitamin D deficiency is abundant at the time of diagnosis 
and can safely be targeted to a level of 75-150 nmol/L through vitamin D 
supplementation in doses of 50-100 ug daily (conversion 1 ug = 40 international 
units, IU) (Soilu-Hänninen et al., 2008; Åivo, Lindsröm and Soilu-Hänninen, 2012; 
Pierrot Deseilligny and Souberbielle, 2013; Hoel et al., 2016; Pierrot-Deseilligny 
and Souberbielle, 2017).  
MS patients have lower vitamin D levels during relapse than remission (Soilu-
Hänninen et al., 2005, 2008; Correale, Ysrraelit and Gaitn, 2009), and an inverse 
association between relapse rate and 25(OH)D levels has been observed in MS 
patients with POMS and  adult-onset disease (Mowry et al., 2010; Simpson et al., 
2010; Runia et al., 2012). Vitamin D association with MS progression is less clear, 
but low levels at the start of RRMS have been associated with earlier SPMS 
conversion in a retrospective longitudinal 3-year follow-up study, indicating an 
association between vitamin D deficiency and early SPMS conversion (Muris et al., 
2016). Higher vitamin D levels in early MS disease course have been shown to 
predict reduced disease activity, MRI brain atrophy and lesion load as well as 
reduced clinical disease progression (Ascherio et al., 2014). Serum 25(OH)D levels 
inversely correlate with MRI activity demonstrated by Gd-enhancing lesions and 
new T2 lesions (Løken-Amsrud et al., 2012; Mowry et al., 2012). 
However, accumulated data on vitamin D supplementation effect in MS 
treatment has been inconsistent (James et al., 2013; Jagannath et al., 2018; 
McLaughlin et al., 2018; Zheng et al., 2018). A systematic review and meta-analysis 
of 5 randomized clinical trials (RCTs), showed that vitamin D supplementation was 
not beneficial in controlling MS relapses (OR 0.98, 95% CI 0.45–2.16) (James et al., 
2013), nor did D3 appear to have therapeutic effect on EDSS score (mean difference 
– 0 .01, 95% CI -0.34–0.33) or ARR (mean difference 0.05, 95% CI 0.01–0.1) in a 
meta-analysis evaluating these clinical outcome measures in RCTs performed prior 
to 2017 (Zheng et al., 2018).  
However, these previous systematic reviews on vitamin D for the clinical 
efficiency of MS have had some limitations that were addressed in a recent 
systematic review of RCTs which found disease outcome improvement (EDSS, 
ARR, serum 25(OH)D levels, quality of life, cytokine profile, mobility, MRI T2 
lesion load and new T2 or Gd-enhancing T1 lesions, safety and AEs) in 3 out of 10 
trials, pointing to a conclusion that vitamin D supplementation benefit may be most 
apparent in MS subjects with lower baseline vitamin D levels (Berezowska, Coe and 
Dawes, 2019). Also, another meta-analysis from 2018 concluded that vitamin D 
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supplementation might have a therapeutic role in MS, whereas there is uncertainty 
with regard to the appropriate dose (McLaughlin et al., 2018), warranting future 
well-performed dose-ranging, placebo-controlled RCTs. If successful, trials will 
help answer the questions of when, how much, and what type of vitamin D the 
patients with MS should be supplemented with, as well as what level of serum 
vitamin D should be targeted for optimal benefit (Cree, 2014). Since September 
2017, there is also an ongoing comprehensive systematic review and meta-analysis 
of RCTs on vitamin D supplementation in MS, aimed at assessing the effectiveness 
of vitamin D supplementation on clinical and para-clinical outcomes (ARRs, EDSS, 
Gd-enhancing lesions of MRI and cytokine levels of tumor necrosis factor and IL as 
the main outcomes) in patients with MS (Ghajarzadeh et al., 2019). 
Serum vitamin D levels may be a predictor of improvements in disease pathology 
from vitamin D supplementation, suggesting 25(OH)D levels in serum and initial 
calcemia should be screened for before initiation of supplementation and followed 
up six months after initiation and then annually to check for compliance. Until dose-
ranging, placebo-controlled RCTs give conclusive answers, levels above the 
estimated beneficial plateau (100-150 nmol/L) should not be exceeded due to lack 
of beneficial evidence and an increased risk of AEs (Berezowska et al., 2019; 
Pierrot-Deseilligny and Souberbielle, 2017). 
In a randomized placebo-controlled trial in Finnish MS patients, cholecalciferol 
supplementation at a dose of 20,000 IU/week lead to serum 25(OH)D levels of 
approximately 100 nmol/L and significantly less Gd-enhancing T1 lesions with good 
safety and no treatment-related AEs (Soilu-Hänninen et al., 2012). Vitamin D 
supplementation is already implemented in the national treatment guidelines for MS 
patients in Finland, and recommended at a daily oral dose of 50-100 ug to reach 
serum 25(OH)D levels of ≥100 nmol/L in particular among MS patients with low 
vitamin D levels (Multiple Sclerosis: Current Care Guidelines Abstract, 2019). 
Supplementation may have beneficial effects on the early inflammatory component 
of MS disease and should be continuous in temperate zones since vitamin D storage 
is short-lasting (up to 6 weeks) in the organism and risk of vitamin D deficiency is 
continuous at latitudes with low annual UVB radiation (Pierrot-Deseilligny and 
Souberbielle 2017; Berezowska et al., 2019). 
2.1.5 Pathogenesis of MS 
2.1.5.1 Role of inflammation and neurodegeneration in MS 
MS is a chronic autoimmune neurological disease associated with CNS 
inflammation and neurodegeneration mediated by the adaptive and innate arms of an 
unregulated immune response (Compston and Coles, 2008; Hollenbach and 
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Oksenberg, 2015; Murdaca et al., 2019). Clinical disease expression is heterogenous, 
varying from mild “benign” MS to rapidly disabling disease. The primary trigger of 
the upregulated immune response in MS remains unknown, but in the early 
inflammatory cascade, a response is triggered against myelin antigens, such as 
myelin basic protein, proteolipid protein, myelin-associated glycoprotein, MOG, and 
gangliosides. In early disease, the myelin surrounding the nerve cell axons is affected 
and injured, causing various clinical symptoms and pathological white matter lesions 
visual to the eye (widespread scars) (Waxman, 1982; Compston and Coles, 2008; 
Howard, Trevick and Younger, 2016). The myelin sheaths surrounding the axons are 
built by oligodendrocytes, supportive cells under a family of glial cells, of which 
astrocytes are the most common. In CNS damage, astrocytes increase in number 
causing the visible lesions in imaging. MS pathology is characterized by focal 
inflammatory infiltrates, breakdown of myelin sheaths, microglia activation, 
proliferation of astrocytes, gliosis, as well as various grades of axonal degeneration 
associated with oxidative stress and mitochondrial injury (Lassmann, 2014; Simons, 
Misgeld and Kerschensteiner, 2014). Demyelinated lesions are disseminated in the 
CNS and MS involves both white and gray matter (Geurts et al., 2012; Gh Popescu 
and Lucchinetti, 2012; Hollenbach and Oksenberg, 2015; Howard, Trevick and 
Younger, 2016). Circulating autoimmune T-cells are triggered to activation by 
unknown target antigens, possibly as a result of cross-reactivity, and adhere to blood 
vessel walls and migrate across the BBB into the CNS, where they recognize cells 
presenting myelin fragments on the human leukocyte antigen (HLA) complex, to 
which the T-cells connect and cause further inflammation through the release of 
signal substances (cytokines) that increase the inflammation and attract macrophages 
(Kawanokuchi et al., 2008; Stinissen and Hellings, 2008; Bartholomäus et al., 2009; 
Hemmer, Kerschensteiner and Korn, 2015)(Sospedra and Martin, 2016). CD4+ Th1 
cells were considered to be the main effectors, but more recently Th17 cells were 
identified as the primary effectors (Langrish et al., 2005; Korn et al., 2009). 
Suppressor T-cells (T regulatory cells, Tregs) have an antagonistic role in this 
cascade of events, but their function is impaired in MS, contributing to the disease 
mechanisms (Viglietta et al., 2004; Workman et al., 2009). B-cells produce auto-
antibodies against myelin and bind to the myelin, as do blood proteins of the 
complement system, facilitating the damage caused by tissue-consuming 
macrophages that release myelin degrading enzymes (Cepok et al., 2005). B cells, 
plasma blasts and plasma cells, which produce immunoglobulins (Ig) detected as 
OCBs in the CSF, are adjacent in meninges, plaques and CSF of most MS patients 
(Esiri, 1980; Henderson et al., 2009). 
Histologically, CNS lesions are classified as acute, chronically active and 
inactive, with the acute lesions demonstrating marked perivascular inflammatory cell 
infiltrates, composed mainly of T cells, macrophages, mononuclear cells, B- and 
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plasma cells. Demyelination eventually ensues, with phagocytosis of myelin debris 
by microglial cells and macrophages. The myelin-producing oligodendrocytes are 
destroyed by inflammatory infiltration and gliosis, resulting in demyelination-
associated reduced nerve conduction, conduction block and various clinical 
symptoms such as numbness, pain, burning, itching, motoric deficits, ON and 
balance disturbances. Cognitive symptoms include memory disturbances, decreased 
judgement, fatigue and inattention. Remyelination is activated by oligodendrocyte 
progenitor cells. Axonal injury is associated with the inflammation in active MS 
lesions, whereas the axonal loss found on histological examination is likely 
responsible for the chronic and progressive symptoms in MS. Later in the disease 
course, clinically silent acute lesions may contribute to axonal injury (Howard, 
Trevick and Younger, 2016).  
2.1.5.2 Genetic risk factors 
Clustering of MS-affected individuals in families and a high concordance rate in 
monozygotic twins (MZ) pose some evidence of a genetic component to the disease. 
MZ twins run a ∼17% risk of developing MS disease, compared to 2% for dizygotic 
(DZ) twins and siblings in general, as well as for offspring of a parent with MS, 
whereas the risk is about 0.2% for the general population in northern Europe 
(Westerlind et al., 2014, 2015). In a Finnish MS twin study from 2008, the 
concordance rate among twins had increased over 20 years, suggesting that the 
reported increase in MS incidence in Finland is predominantly caused by 
environmental factors. The pairwise concordance was 30% for MZ twins and 14.3% 
for DZ twins, and the corresponding proband-wise concordance rates were 46.2% 
and 25%. The genetic variance (heritability) was 15%, the common environmental 
variance 73.3% and the unique environmental variance 11.1% (Kuusisto et al., 
2008). There is broad consensus that MS disease is multifactorial and that the MS-
prone genotype results from various independent and interacting polymorphic genes 
with risk alleles common in the population, each exerting a small impact on the 
overall risk in interaction with additional risk factors at an individual level (Anna 
Karin Hedström, Sundqvist, et al., 2011; Hedström, Bomfim, et al., 2014; 
Hollenbach and Oksenberg, 2015; Baranzini and Oksenberg, 2017; Hedström, 
2019).  
The association between specific HLA variants within the major 
histocompatibility complex (MHC) gene complex (chromosome 6p21) and MS was 
first established in the 1970s (Compston and Coles, 2008). Genes encoding antigen-
presenting molecules within the MHC region seem to account for the majority of the 
genetic MS risk (Hollenbach and Oksenberg. 2015; Baranzini and Oksenberg, 2017). 
HLA genes are recognized to have a critical role in histocompatibility and transplant 
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outcome and are associated with many infectious, inflammatory, autoimmune and 
pharmacological disease phenotypes and cancers.  
HLA-class I molecules HLA-A, -B, and –C primarily bind and present peptides 
from endogenous synthesized proteins (such as viral and tumor peptides) to CD8+ 
T-cells and serve as ligands for the killer immunoglobulin-like receptors on the 
surface of natural killer (NK) cells. The class II molecules, HLA-DR, -DQ, and -DP, 
are associated as heterodimers on the cell surface of antigen-presenting cells such as 
B cells, dendritic cells (DC) and macrophages, and serve as receptors for processed 
peptides derived from membrane and extracellular proteins (bacterial peptides) 
presented primarily to CD4+ T-lymphocytes (Sollid, Pos and Wucherpfennig, 2014; 
Hollenbach and Oksenberg, 2015).   
HLA association with both RRMS and PPMS risk has been observed across all 
populations studied. The HLA-DRB1*15 allele contributes to increased risk of MS 
with an OR of approximately 3 in most populations, and accounts for approximately 
11% of MS heritability. This gene has a vitamin D-responsive element (VDRE) zone 
in the promoter region, strongly suggesting an involvement in mechanisms linked to 
vitamin D (S. V Ramagopalan et al., 2009; Laursen et al., 2015). Other HLA-DRB1 
alleles have also been independently associated with increased MS risk (Hollenbach 
and Oksenberg, 2015; Hedström, 2019)(Seboun et al., 1999).  
Genome-wide association studies (GWAS) and hypothesis-driven studies with 
extensive complementary genome coverage of selected regions have resulted in over 
100 identified MS risk variants at 103 loci outside of the MHC (Beecham et al., 
2013; Baranzini and Oksenberg, 2017). A majority of these loci encode immune-
response proteins involved in the main stages of MS pathogenesis (Bashinskaya et 
al., 2015; Harirchian et al., 2018)(Sawcer, Franklin and Ban, 2014). Despite a large 
number of gene loci associated with MS risk, they account for only half of the disease 
heritability (Patsopoulos, 2018).  
The HLA-A*02:01 allele exerts a protective effect on MS risk (OR 0.7) 
(Brynedal et al., 2007; Bergamaschi et al., 2010; Sawcer, Franklin and Ban, 2014; 
Hedström, 2019).   
2.1.5.3 Environmental risk factors 
Findings from studies of genetic impact on MS disease strongly argue for 
environmental exposures playing an essential role in determining disease risk, and 
these are important to define since they can be modified and MS occurrence 
potentially preventable (Faridar et al., 2012; Eskandari et al., 2015; Mokry et al., 
2016; Correale, Farez and Gaitán, 2017; Alfredsson and Olsson, 2019; Simpson et 
al., 2019). 
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Table 4.  Established and possible lifestyle and environmental risk factors for MS 
 
The level of evidence for the role of a particular lifestyle or environmental factors in MS is not easy 
to define. Large prospective studies are, with a few exceptions, rare in MS. CMV, cytomegalovirus; 
EBV, Epstein-Barr virus; HLA, human leukocyte antigen; MS, multiple sclerosis; NA, not applicable; 
OR, odds ratio; +++, high level of evidence: drawn from large prospective studies or if case-control 
observation is supported by Mendelian randomization studies; ++, Case-control observations, if 
replicated and/or supported by independent methods; +, Non-replicated observations (included to 
enable further observations). Table reprinted with permission (Olsson, Barcellos and Alfredsson, 
2016). 
Genetic predisposition and female gender only explain a fraction of MS risk increase, 
and there is strong evidence for associations with environmental influence, such as 
EBV infection, exposure to tobacco smoke, limited sun exposure/low vitamin D, 
high latitude gradient and adolescent obesity (Munger, Chitnis and Ascherio, 2009; 
Simpson et al., 2011, 2019; Ascherio, Munger and Lünemann, 2012; Munger et al., 
2013; Lucas et al., 2015). The changes in risk that occur with migration cannot be 
explained by genetics but rather support the impact role of environmental factors 
(Isobe et al., 2013; Ascherio and Munger, 2016). Accumulated evidence suggests 
that the risk of developing MS is determined by a combination of genetic and 
environmental factors (Olsson et al. 2017). The environmental risk factors for MS 
can influence both adaptive and innate immunity. Certain risk factors, including 
EBV infection, smoking and obesity, interact with HLA MS risk genes and argue for 
shared pathogenic pathways involving adaptive immunity (Olsson, Barcellos and 
Alfredsson, 2016). 
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2.1.5.3.1 Epstein-Barr virus and risk of MS 
EBV or human herpesvirus 4 (HHV-4) is a γ-herpesvirus that infects up to 95% of 
the adult population (Saha and Robertson, 2019). Primary infection is orally 
transmitted and occurs in oropharyngeal epithelial cells. In early childhood, the 
primary infection is usually benign but can cause the syndrome of infectious 
mononucleosis (IM) if attracted in adolescence or early adulthood. EBV mainly 
infects B cells and epithelial cells of the oral mucosa, as well as T  or NK lineage 
cells, and following resolution of the primary infection, the virus persists in 
circulating memory B cells (Lindsey, 2012). The EBV life cycle in humans can be 
divided into a lytic replication phase in epithelial cells and a lifelong latent phase, 
periodically reactivating (Murata and Tsurumi, 2014). Antibodies to some EBV 
antigens persistently remain detectable (indicating recurrent antigenic stimulation). 
In the vast majority of non-immunocompromised individuals, the virus causes no 
apparent disease, and is well adapted to co-existence with its human host. In 
immunosuppressed hosts, however, EBV can cause lymphoproliferative disorders 
and the virus has been associated with some neoplasms (various lymphomas, 
nasopharyngeal and gastric carcinomas), as well as some autoimmune diseases 
(Lindsey, 2012).  
The association between EBV and MS was suggested for the first time almost 
five decades ago (Tourtellotte, 1971), and has been substantiated in numerous 
subsequent studies. EBV remains the most pertinent of the many infectious agents 
that have been suggested to play a role in MS development (Ascherio and Munger, 
2007), and although causality is debated, collective circumstantial evidence is 
compelling (Ascherio and Munger, 2010; Alfredsson and Olsson, 2019). More than 
99% of MS patients are seropositive for EBV, and the odds ratio (OR) for MS is 0.00 
in seronegative individuals (Pakpoor, Disanto, et al., 2013). EBV has been identified 
as a risk factor for MS in Caucasian, Afro-American and Latin American populations 
(Langer-Gould et al., 2017). 
In MS studies, EBV antibodies (Abs) of interest include those to the restricted 
and diffuse forms of early antigen (EA-R, EA-D), viral capsid antigen (VCA) and 
EBV nuclear antigen (EBNA, including six proteins EBNA-1, EBNA-2, etc.). Ab 
titers can be detected with various methods (e.g. immunofluorescence, IF; enzyme-
linked immunosorbent assays, ELISA) (Henle and Henle, 1966; Reedman and Klein, 
1973; Lindsey, 2012). Abs to VCA appear soon after primary infection (IgM) and 
later remain detectable (IgG) during latency, whereas Abs to EA are usually 
undetectable after the acute infection has resolved but may reappear during viral 
reactivation. EBNA Abs appear during resolution of primary infection and remain 
detectable during latency. Almost all EBV studies on MS risk association have 
measured mainly serum IgG Abs (as compared to IgM or IgA, and CSF Abs) 
(Lindsey, 2012). 
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Primary EBV infection is a strong risk factor for MS, and almost all case-control 
studies comparing the prevalence of EBV infection or EBV Ab titers in MS with 
controls have found a significant increase in the MS group. IgG Abs to EBNA and 
VCA are both increased, with higher significance for EBNA if tested in the same 
study (Lindsey, 2012). EBNA-1 and VCA Abs, at various degrees in separate 
studies, are increased also among CIS subjects (Lünemann et al., 2010; Lucas, A.- 
L. Ponsonby, et al., 2011). A previously conducted prospective nested case-control 
study showed that all primarily EBNA1-seronegative subjects had converted before 
MS onset (Levin et al., 2010), suggesting EBV infection may be a prerequisite for 
development of adulthood MS. Increasing IgG Ab titers against EBNA have been 
associated with an increased MS risk in healthy adults (Ascherio and Munger, 2016). 
EBNA1 Ab titers positively correlate with MS occurrence and higher titers are found 
among MS subjects compared to controls (Sundström et al., 2009; Sundqvist et al., 
2012; Zhou et al., 2016), which can be interpreted as evidence for causality of EBV 
in MS. EBV infection during adolescence or later is associated with an increased risk 
for developing MS, whereas this does not seem to be the case for infection during 
childhood (Ascherio and Munger, 2015). Individuals who have incurred clinically 
overt IM have a >2- fold risk to develop MS (S. V. Ramagopalan et al., 2009; Handel 
et al., 2010). These findings suggest that there is a specific window of time for when 
EBV infection implies a higher risk for MS. A recent study on whether remote 
infection with EBV and other common herpesviruses affect susceptibility of 
pediatric MS strongly linked EBV-VCA seropositivity to associate with a 7.4-fold 
increased risk (Nourbakhsh et al., 2018). Several studies suggest that prevalence of 
EBV infection is also increased in children with MS (Banwell et al., 2007), although 
unlike the adult MS population, a significant minority of children are not EBV-
infected. To test for the causality of EBV in MS, Abs should be tested years before 
disease onset. Previously conducted prospective studies have found that EBNA and 
EBNA-1 Abs were most predictive of MS risk in adults (Sundström et al., 2004; 
Munger et al., 2011). In studies on EBV correlation with disease activity, there is 
evidence suggestive of increased anti EA-Ab association with more active MS 
disease (Wandinger et al., 2000; Buljevac et al., 2005). 
HLA risk genes and IM seem to interact synergistically in increasing the risk of 
MS. An interaction between anti-EBV titers and these genes has been observed 
leading to a 16-fold higher risk of MS associated with abundance of HLA-
DRB1*15:01 and absence of HLA-A*02 in combination with high EBNA 385-420 
IgG titers compared to individuals who did not carry any of these factors (Sundqvist 
et al., 2012). An interaction between obesity and a history of IM during adolescence 
has been associated with an increased MS risk with an OR of approximately 14. This 
finding suggests that the HLA risk alleles that encode molecules regulating T cell 
adaptive immunity might show common pathogenic pathways triggering MS when 
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they interact with measures of EBV infection (Hedström et al., 2015). One study that 
has not been replicated with similar findings detected EBV-related DNA in CNS 
lymphoid infiltrates (Serafini et al., 2007). Anti-CD20 treatments that deplete B 
cells, in which EBV resides latent, are effective in MS (Hauser et al 2008), providing 
some support for the EBV hypothesis. Of many suggested theories, one possible 
explanation of the mechanism by which EBV might trigger MS is molecular 
mimicry, by sharing antigen epitopes with a brain antigen and thus, through cross-
reactivity, provoking CNS autoimmunity associated with EBV reactivation 
(Esposito et al., 1999; Gabibov et al., 2011).  
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2.1.5.3.2 Smoking and risk of MS 
Already a decade ago, at least 8 epidemiologic studies investigating smoking as an 
environmental risk factor for MS had found support for the supposition (Antonovsky 
et al., 1965; Thorogood and Hannaford, 1998; Ghadirian et al., 2001; Hernán, Olek 
and Ascherio, 2001; Zorzon et al., 2003; Hernán et al., 2005; Pekmezovic et al., 
2006). Since then, epidemiological evidence for an association between smoking and 
MS risk has rapidly increased (Hawkes, 2007; Hedström et al., 2009; Handel and 
Ramagopalan, 2011; Handel et al., 2011; Wingerchuk, 2012; Salzer et al., 2013; 
O’Gorman and Broadley, 2014; Zhang et al., 2016; Degelman and Herman, 2017; 
Poorolajal et al., 2017; Hedström, 2019). Smoking also contributes to worse outcome 
in MS, earlier conversion from CIS to definite MS and from RRMS to SPMS and 
accelerates disease progression (Sundström and Nyström, 2008; Healy et al., 2009; 
Correale and Farez, 2015; Ramanujam et al., 2015)(Manouchehrinia et al., 2013).  
Prior study observations suggest that smoking is an independent risk factor for 
MS (Hedström et al., 2009), and this risk may be modified by interaction with other 
genetic and environmental risk factors, whereas the role of smoking in MS 
progression is more controversial (Arruti et al., 2015). Adult tobacco smokers of 
both sexes run an increased risk of developing MS compared to never-smokers (OR 
1.5, 95% CI 1.3–1.8) and there is a dose-response correlation between MS risk and 
cumulative dose of smoking (OR 1.8 and 1.4 for female and male subjects, 
respectively), which remain up to 5 years after smoking cessation (Hedström et al., 
2009). Serum levels of cotinine, the metabolite of nicotine used as an objective 
marker for cigarette smoking, have also been associated with a 1.5 OR increase in 
◄ Figure 1.  Proposed role of EBV infection in the development of MS. EBV infects autoreactive 
naïve B cells in the tonsil, driving them to enter germinal centers where they proliferate 
intensely and differentiate into latently infected autoreactive memory B cells (Step 1), 
which then exit from the tonsil and circulate in the blood (Step 2). The number of EBV-
infected B cells is normally controlled by EBV-specific cytotoxic CD8+ T cells, which kill 
proliferating and lytically infected B cells, but not if there is a defect in this defense 
mechanism. Surviving EBV-infected autoreactive memory B cells enter the CNS where 
they take up residence and produce oligoclonal IgG and pathogenic autoantibodies, 
which attack myelin and other components of the CNS (Step 3). Autoreactive T cells 
that have been activated in peripheral lymphoid organs by common systemic infections 
circulate in the blood and enter the CNS where they are reactivated by EBV-infected 
autoreactive B cells presenting CNS peptides (Cp) bound to major histocompatibility 
complex (MHC) molecules (Step 4). These EBV-infected B cells provide costimulatory 
survival signals (B7) to the CD28 receptor on the autoreactive T cells and thereby inhibit 
the activation induced T cell apoptosis, which normally occurs when autoreactive T cells 
enter the CNS and interact with non-professional antigen-presenting cells such as 
astrocytes and microglia, which do not express B7 costimulatory molecules132–134 
(Step 6). After the autoreactive T cells have been reactivated by EBV-infected 
autoreactive B cells, they produce cytokines such as interleukin-2 (IL2), interferon-γ 
(IFNγ) and tumor necrosis factor (TNFβ), and orchestrate an autoimmune attack on the 
CNS with resultant oligodendrocyte and myelin destruction (Step 5). Reproduced 
(Pender and Burrows, 2014) with permission (Pender, 2011).  
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MS risk (Salzer et al., 2013). Use of snuff over 15 years, on the other hand, decreases 
MS risk (OR 0.3, 95% CI 0.1–0.8) (Hedström et al., 2009). Simultaneous use of 
snuff and smoked tobacco exert antagonistic effects on risk of developing MS, 
suggesting that nicotine is an unlikely compound to account for the association 
between smoking and increased MS risk (Hedström et al., 2013). There is some 
evidence supporting a possible neuroprotective feature of nicotine in several 
conditions and possibly in MS (De Jonge and Ulloa, 2007; de Saussure et al., 2007; 
Picciotto and Zoli, 2008). Nicotine may exert systemic effects on the immune system 
through inhibition of the production of proinflammatory cytokines from immune 
cells, such as macrophages, via the α7-subunit of the acetylcholine nicotinic receptor 
(De Jonge and Ulloa, 2007; Tracey, 2007). However, clinical evidence of beneficial 
nicotine use is still missing (Kaakkola and Tuominen, 2013).  
Exposure to environmental tobacco smoking (secondhand smoking, SHS) is 
associated with increased risk for MS in non-smokers (A. K. Hedström et al., 2011) 
and parental smoking has been associated with risk of MS in offspring (Mikaeloff et 
al., 2007), whereas no risk increase in early onset MS among offspring exposed to 
parental smoking during pregnancy has been demonstrated (Montgomery et al., 
2008). The pathogenesis and biological mechanism linking tobacco and MS risk is 
unknown. A variety of mechanisms have been suggested, such as the potential of 
nicotine to increase microvascular bloodflow and to cause leakage in the BBB, which 
is a suggested initiating event of MS (McDonald, 1994). Another explanation is 
immunotoxicity by impairment of antigen-mediated signaling in T cells (Hans et al., 
1993; Sopori and Kozak, 1998; Kalra et al., 2000) or an elevation in peripheral blood 
leucocyte counts and important inflammation markers (such as C-reactive protein 
and IL-6). Impairment of humoral- and cell-mediated immunity and abnormalities 
in T cell function have been observed in smokers (Hughes et al., 1985; Petitti and 
Kipp, 1986; Moszczyński et al., 2001; Bermudez et al., 2002).  
Smoking increases the risk of MS by approximately 50%, with considerable 
variations in different contexts, populations and subjects. A significant interaction 
between smoking and two genetic risk factors, carriage of HLA DRB1*15 and 
absence of HLA A*02, has been described, suggesting that the risk of MS disease 
associated with HLA genotypes may be strongly influenced by smoking (Anna Karin 
Hedström, Sundqvist, et al., 2011). The strongest genetic associations with MS are 
located within the HLA complex and having the primary risk allele class II HLA-
DRB*1501 increases the MS risk 3-fold in the Scandinavian populations. Protective 
genes include class I allele HLA-A*02 (OR 0.7). Having HLA-DRB*15:01 and 
lacking HLA-A02* results in a combined OR of 5 among non-smokers and an OR 
of 14 for smokers. The genetic component has been estimated at 50% of the 
contribution to MS (Hedström, 2019). 
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Mechanisms linking smoking to MS risk are speculated to involve lung 
inflammation with a proinflammatory profile, as the interaction with MS risk HLA 
genes argues for an action on adaptive immunity, possibly by activation of auto-
aggressive cells resident in the lungs subsequently attacking the CNS (Hedström, 
2019). Possible interactions between lung irritative agents and HLA genes with 
regard to MS risk have been described to be consistent with class II allele-specific 
recognition of autoantigenic peptides in the lungs, resulting in organ-specific 
inflammatory disease. For MS, absence of HLA-A*0201 may result in autoreactive 
T cells persisting and launching an immune response against the self-antigen. 
Epidemiologic and experimental studies support the hypothesis that different sources 
of lung irritation may contribute to induce an immune reaction against modified self-
proteins or against potentially auto-aggressive cells resident in the lungs, and 
promote MS development in genetically susceptible subjects (Doyle and Mamula, 
2002; Cloos and Christgau, 2004; Makrygiannakis et al., 2008; Odoardi et al., 2012; 
Hedström et al., 2018). 
2.1.5.3.3 Vitamin D and risk of MS 
The first study to link vitamin D status with MS risk was a prospective study among 
nurses in US, which found that higher dietary intake of vitamin D was associated 
with lower MS risk (Munger et al., 2004). Another study performed in US women 
found that gestational dietary vitamin D intake was associated with a decreased MS 
risk in the offspring (Mirzaei et al., 2011). Supplementation during pregnancy, early 
childhood and adolescence can lower the risk of MS disease in the offspring 
(Chaudhuri, 2005), although study observations on vitamin D benefit during 
pregnancy as MS protective for the offspring have been inconsistent (Salzer et al., 
2012; Ueda et al., 2014). The effect of maternal vitamin D deficiency during 
pregnancy and MS risk in offspring has not been studied previously. 
Serum levels of 25(OH)D ≥100 nmol/L were associated with an approximately 
60% decreased risk of developing MS in non-Hispanic Caucasian patients from a US 
war veterans’ cohort (Munger et al., 2006). In a Swedish study, women with serum 
levels of 25(OH)D ≥75 nmol/L from pregnancy gestational samples were associated 
with an odds ratio of 0.39 for developing MS (Salzer et al., 2012). High sun exposure 
has been shown to be protective against MS and low sun exposure as an MS risk factor 
(Ascherio, Munger and Lünemann, 2012). A study from Tasmania from 2003, that 
used skin actinic damages as a measure UV radiation exposure, found that higher sun 
exposure during childhood and early adolescence was associated with a reduced risk 
of MS (Van Der Mei et al., 2003). A significant association between infrequent 
summer outdoor activity and increased MS risk has been found in Norway and in Italy 
(Bjørnevik et al., 2014). Another study performed in Australia showed that sun 
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exposure and vitamin D are independent risk factors for CNS demyelination (Lucas, 
A-L Ponsonby, et al., 2011).  Vitamin D production in the skin induced by UV 
radiation is the main source of vitamin D3 in humans (Holick et al., 1980), but the 
independent effects on MS risk of both UV radiation and vitamin D deficiency have 
demonstrated how complexly UV radiation and vitamin D status interact with one 
another and the risk of developing MS (Ascherio and Munger, 2016). 
 Opinion about whether there is sufficient evidence to conclude that low sun 
exposure and vitamin D increase the risk of multiple sclerosis is divided. General 
public health advice to receive sufficient sun exposure to avoid vitamin 
D insufficiency (<50 nmol/L) should also ensure any benefits for multiple sclerosis, 
but must be tempered by the risk of skin cancers (Amato et al., 2018).  
2.1.5.3.4 Socioeconomic and lifestyle factors and risk of MS 
Lifestyle and environmental factors may act years before the clinical onset of MS, and 
many individuals present with multiple CNS lesions on MRI at clinical onset of MS, 
suggesting a subclinical phase of several years (Marrie et al., 2013) altered by 
predisposing risk factors years before MS onset. Most lifestyle and environmental 
factors appear to have the greatest impact during adolescence (Olsson, Barcellos and 
Alfredsson, 2016). Migration studies show that MS risk depends on the age of 
migration so that those migrating from a low-risk country to a high-risk country before 
adolescence show a MS risk much similar to that of the high-risk country (Gale and 
Martyn, 1995; Ahlgren et al., 2010; Simpson et al., 2011)(Berg-Hansen et al., 2015). 
Whether this is related to changed environment or lifestyle changes is difficult to 
distinguish. The availability of functioning health care systems, neurologists, and 
diagnostic tools (e.g. MRI) that have improved in the last decades may add to the 
reported increase in worldwide MS prevalence and incidence (Howard, Trevick and 
Younger, 2016) but does not explain the rapid globally increased female predominance 
of RRMS. This observation may more likely be linked to risk factors affecting women 
(e.g. increased obesity, smoking, and reproductive behavior changes).  
The first association between obesity and MS was found in a US study, where 
women with a body mass index (BMI) ≥30 kg/m2 at age 18 had a 2.25-fold increased 
risk of developing MS compared to normal-range BMI subjects (18.5 to < 21 kg/m2) 
after adjusting for age, latitude at age 15, ethnicity and smoking. There was no 
association between baseline BMI and MS risk (Munger, Chitnis and Ascherio, 2009). 
Confirming findings of a ∼two-fold MS risk associated with various ages of adolescent 
obesity were found for both male and female subjects in studies on Swedish, 
Norwegian and Italian populations (Hedström, Olsson and Alfredsson, 2012; Wesnes 
et al., 2015). Childhood obesity mainly among girls has also been associated with 
increased risk of POMS, CIS and adult-onset MS (Langer-Gould et al., 2013; Munger 
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et al., 2013). Childhood obesity is strongly associated with adolescent and adulthood 
obesity (Deshmukh-Taskar et al., 2006). Obesity interacts with genetic and 
environmental factors to increase the odds for MS, as shown in a study including data 
from case-control studies in the US and Sweden. A BMI of ≥27 kg/m2 in young 
adulthood combined with HLA-DRB*15 risk alleles increased MS risk 7-fold 
compared to non-carriers of MS risk alleles with a BMI of <27. Similarly, for obese 
HLA-A*02 carriers, the risk for MS was significantly elevated (Hedström, Bomfim, 
et al., 2014). A significant interaction between adolescent obesity and IM (EBV) 
associated with a 6-fold MS risk increase has also been reported, further increasing the 
obesity-associated MS risk (Hedström et al., 2015). Biological mechanisms 
underlying the association between MS and obesity are unknown, but one plausible 
mechanism is linked to lower levels of circulating vitamin D among adults and 
children (Parikh et al., 2004; Smotkin-Tangorra et al., 2007). Smoking, EBV infection 
and obesity interact with HLA immune response risk genes such that MS risk 
increases, suggesting a pathogenic pathway of action involved in adaptive immunity, 
leading to autoimmune attack on the CNS (Olsson, Barcellos and Alfredsson, 2016).  
Occupational exposures to organic solvents, including painting products and 
varnish, have been associated with MS proneness, increasing the risk (OR 1.5, 95% 
CI 1.2–1.8, P = 0.0004) among both never and ever smokers, and an increased risk 
for MS associated with carriage of HLA-DRB1*15 and absence of HLA-A*02 
alleles (Hedström et al., 2018).  
In addition to ethnicity, socioeconomic status (SES) affects the risk of 
developing MS, with both high and low SES associated with MS risk in different 
studies. Those studies reporting an MS increase association with low SES came from 
more egalitarian countries, whereas association between increased MS risk and high 
SES were reported from more unequal countries (Goulden, Ibrahim and Wolfson, 
2015). An adverse socioeconomic status in childhood and adulthood is associated 
with a proinflammatory phenotype and is therefore an important exposure to 
consider. In one Californian population-representative case-control study, the OR 
for MS, associated with the socioeconomic statuses of childhood and adulthood, 
were significantly higher for factors such as parents renting versus owning a home 
(at age 10 of the cohort child), lower versus higher educational level, low versus high 
life course and low versus high social mobility (Briggs et al., 2014). In a Danish 
population-based case-control study evaluating socioeconomic and reproductive 
factors associated with MS risk (especially with the increased MS prevalence among 
women), found that having newborn children reduced MS risk in women but not in 
men, and childbirths reduced the risk of MS by about 46% during the following 5 
years. Terminated pregnancies also seemed to have a protective effect on the risk of 
MS occurrence. Socioeconomic status, educational level and sanitary conditions in 
youth did not show an association with MS risk (Magyari, 2015).  
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In addition to EBV, many other viruses have been suggested to play a role in 
increasing MS risk, including two other herpes viruses, human herpes virus-6 (HHV-
6, which infects T lymphocytes, neurons and oligodendroglia, among others) and 
varicella zoster virus (VZV). Some studies have shown that HHV-6 DNA and 
proteins can be detected in neurons and oligodendrocytes near MS plaques, virus 
reactivation in blood correlates with MS disease activity, and high antibody titers 
have been shown to predict an increased MS risk (Challoner et al., 1995; Sundström 
et al., 2004; Höllsberg et al., 2005), whereas the evidence linking VZV and MS is 
even more controversial (Lindsey, 2012). On the other hand, human cytomegalovirus 
(CMV) may have a protective role in MS (Bray et al., 1983).  
 
Figure 2.  Lifestyle and environmental factors affect the immune system to trigger and/or 
perpetuate multiple sclerosis. Depicted here are lifestyle and environmental factors that 
can affect immune system function, which can lead to neuroinflammatory attack on the 
CNS and eventually lead to multiple sclerosis. APC, antigen-presenting cells; Ab, 
antibody; C, complement; CMV, cytomegalovirus; EBV, Epstein–Barr virus; GM-CSF, 
granulocyte monocyte colony stimulating factor; myelin-Ag, myelin antigens; NO, nitric 
oxide; ROS, reactive oxygen species; TC, T cytotoxic cell; TGF-β, transforming growth 
factor β; TH, T helper cell; TNF, tumor necrosis factor; TS, T suppressor cell. Reprinted 
with permission (Olsson, Barcellos and Alfredsson, 2017). 
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Environmental and lifestyle factors associated with reduced MS risk include 
sufficient levels of vitamin D and sun exposure (Ascherio and Munger, 2016), 
serological evidence of CMV infection (Bray et al., 1983; Sundqvist et al., 2014), 
alcohol use (Hedström, Hillert, et al., 2014), high coffee consumption (Hedström et 
al., 2016) and nicotine exposure (snuff) (Alfredsson and Olsson, 2019). There is 
circumstantial evidence of organic solvent and night shift work association with 
increased MS risk (Hedström et al., 2018). Shift work during adolescence may 
increase the MS risk 1.7-fold (Anna Karin Hedström, Akerstedt, et al., 2011). 
Cesarean child delivery (Graves et al., 2017) and breastfeeding have been associated 
with a reduced MS risk in offspring (Conradi et al., 2013; Ragnedda et al., 2015). 
2.2 MS and cancer 
2.2.1 Risk of cancer among MS patients 
In the aging population with MS, comorbidities such as cancer play a growing role. 
In Finland, a total of 250,000 people had had cancer at some point in their lives in 
2011 and there were 30,000 new diagnosed cancer cases. Cancer becomes more 
common with increasing age and the annual number of cancer deaths among Finns 
has remained stable around 11,700, with pulmonary cancer as the most common 
cause of cancer death. The most common cancer in women is BC (n = 4,900) and in 
men prostate cancer (n = 4,700) (Pukkala and Rautalahti, 2013; The Finnish Cancer 
Registry, 2019). 
The immune system plays an important role both in MS and cancer, making it 
plausible that cancer risk is altered in MS. Studies of cancer risk in MS patients have, 
however, been inconsistent (Elaine Kingwell et al., 2012; Tabarés-Seisdedos and 
Rubenstein, 2013; Capkun et al., 2015; Marrie et al., 2015; Roshanisefat et al., 2015; 
Kyritsis, Boussios and Pavlidis, 2016; Thormann et al., 2016). Most studies have 
suggested a reduced overall risk for cancer among MS patients and no effect of long-
term exposure to the immunomodulatory (IM) DMTs GA and IFN. Some studies 
suggest a possible association of DMTs and increased BC risk (Achiron et al., 2005; 
Kingwell et al., 2014), and risk of BC seems to be elevated in the Danish MS 
population (Nielsen et al., 2006). Several reports suggest an increase in cancer risk 
among MS patients treated with traditional IS therapies such as azathioprine, 
cyclophosphamide and MX (Achiron et al., 2005; Lebrun et al., 2008, 2011; Le Bouc 
et al., 2012; Kingwell et al., 2014; Ragonese et al., 2017).  
Because of their action on the immune system, and due to a lack of available 
long-term data, a special warning of the potential risk of cancer accompanies the use 
of recent IS such as cladribine, fingolimod, natalizumab, alemtuzumab, ocrelizumab, 
and possibly DMF and TRF (Bar-or, 2008; Tully, Barkley and Silber, 2015; Ajdacic-
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Gross et al., 2016; McGinley, Moss and Cohen, 2017; Montalban et al., 2017; Sabol 
et al., 2017; Clerico et al., 2017; Coles et al., 2017; Comi et al., 2017; Giovannoni, 
2017; Hauser et al., 2017; Havrdova et al., 2017; D’Amico et al., 2018; Lebrun and 
Rocher, 2018).  
Cancer risk among Finnish MS patients has previously been studied from an 
incidence cohort from 1964 to 1993 followed until year 1999. In a cohort of 1,597 
MS patients, 85 cancers were identified. A small increased risk of hematological 
malignancies and CNS tumors was observed, but no association of overall cancer 
and MS (Sumelahti, Pukkala and Hakama, 2004). Cancer deaths have been 
overrepresented (35%) among MS patients in three different hospital districts, 
compared to the general population in a previous Finnish study (Sumelahti et al., 
2002). There are no previous studies assessing the risk of cancer among Finnish MS 
patients in the era of MS DMTs. 
2.2.2 Smoking and the risk of cancer 
Smoking is the most significant single environmental risk factor for cancer, and 
tobacco contains over 40 carcinogenic substances. Smoking is the cause of 40% of 
cancers in males and 9% in females. Approximately 90% of lung cancers are caused 
by smoking, and smokers run a 10- to 50-fold increased risk of developing lung 
cancer. Other cancers associated with smoking are oral and throat cancers, 
esophageal cancers, pancreas cancer, urinary bladder cancer, cervix cancer, gastric 
cancer, acute myeloid leukemia, mesothelioma and renal cancer, and smoking is 
linked to increased risk for liver, rectal and colon cancer. Smoking seems to increase 
the risk of aggressive prostate cancer, adrenal cancer, biliary cancer and thyroid 
cancer to some extent (Jyrkkiö, Boström and Minn, 2012). The association between 
smoking and BC has been less clear, but in recent well conducted cohort studies, the 
association has been found and is relatively consistent with a 5-32% higher risk for 
current smokers and a 5-18% higher risk for former smokers, compared to never 
smokers (Reynolds et al., 2004; Gram et al., 2005; Olson et al., 2005; Cui, Miller 
and Rohan, 2006; Ha et al., 2007; Xue et al., 2011; Deroo, Cummings and Mueller, 
2011; Luo et al., 2011; Bjerkaas et al., 2013; Rosenberg et al., 2013; Gaudet et al., 
2013; Dossus et al., 2014; Nyante et al., 2014). Smoking has been modestly but 
significantly associated with BC particularly among women who initiated smoking 
at adolescent or peri-menarcheal ages in a UK study. The relative risk for BC 
associated with smoking was greater for patients with a family history of BC (Jones 
et al., 2017). Smoking seems to be associated with BC also among Japanese and 
Americans (Nagata et al., 2006; Gaudet et al., 2013; Nyante et al., 2014) and 
smoking for several years before first childbirth increases the risk of BC (Bjerkaas 
et al., 2013). 
Review of the Literature 
 45 
The mechanisms underlying the development of tobacco-related cancers are only 
partly known. Tobacco products contain several carcinogens, of which the most 
well-known are nicotine derivatives N-nitrosamines, polycyclic aromatic 
hydrocarbon, aromatic amines, aldehydes, phenols, benzene, nitrometan, 
ethylenoxide ad polonium (Huang and Chen, 2011). The cancer-inducing 
mechanisms of tobacco smoke carcinogens are not mapped in detail, but the most 
well-known route of mechanism is mediated through cyclo-oxygenase (COX) and 
its derivates. Smoke carcinogens increase COX-2 expression and activity in many 
cells. The COX-2 derivates prostaglandine E2, thromboxane A2 and prosthacycline 
act in both cardiovascular and cancer pathogenesis. In many cancer cells, an over-
expression of COX-2 has been described (Jyrkkiö, Boström and Minn, 2012).   
2.2.3 EBV infection and the risk of cancer 
EBV is ubiquitous and infects up to 95% of the worldwide population (Saha and 
Robertson, 2019). The virus remains latent in memory B cells and epithelial cells 
and is known to be oncogenic in immunocompromised conditions, and it may also 
cause severe acute diseases as a primary or reactivated infection. EBV can trigger 
malignancies of lymphoid and epithelial origin in humans, and is associated with B 
cell malignancies (Burkitt’s lymphoma and other non-Hodgkin’s lymphomas, 
Hodgkin’s lymphoma, CNS lymphomas, post-transplant lymphoproliferative 
disorder, acquired immunodeficiency syndrome-associated lymphoma, NK 
lymphomas and T cell lymphomas, as well as non-keratinizing nasopharyngeal 
carcinomas and is sporadically linked to some gastrointestinal cancers). The 
oncogenicity of the virus is controlled in immunocompetent individuals but is 
associated in particular with malignancies reflecting primary infection sites, such as 
B cell lymphomas and nasopharyngeal carcinomas in immunosuppressed individuals 
(Andrei, Trompet and Snoeck, 2019). In vitro studies have elucidated the oncogenic 
potential and underlying mechanisms of EBV in B cell lymphomagenesis (Saha and 
Robertson, 2019). In an exploratory study from 2017, a non-random association of 
EBV and BC was seen and differed by age and race, supporting further studies with 
refined design and size (Glaser et al., 2017). 
Some EBV antivirals have been beneficial in vivo, but less successful in the 
clinic and to date no antiviral treatment for EBV has been approved. Interestingly, a 
recent study showed that leflunomide (a drug used to treat rheumatoid arthritis) and 
teriflunomide inhibit EBV-induced lymphoproliferative disease and lytic viral 
replication at a clinically relevant dose in vitro and may therefore be potentially 
useful in clinical prevention of EBV-induced lympho-proliferative disease in the 
near future (Bilger et al., 2017). Novel molecules and strategies aimed at treating 
EBV-related diseases are under investigation (Andrei, Trompet and Snoeck, 2019).  
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2.2.4 Vitamin D and the risk of cancer 
Vitamin D regulates cellular signaling networks and cascades of crucial roles in 
cancer biology and plays a role in processes regulating cell differentiation, 
proliferation, angiogenesis and apoptosis, a discovery that creates potential for 
several applications of vitamin D in cancer (AlMatar et al., 2017; Skrajnowska and 
Bobrowska-Korczak, 2019). Higher levels of circulating 25(OH)D appear to be 
associated with reduced risk for and improved survivorship of certain malignancies 
(McNamara and Rosenberger, 2019). Accumulated data from clinical and preclinical 
investigations suggest that vitamin D deficiency may contribute to carcinogenesis 
risk, and that vitamin D supplementation could potentially contribute to reduction 
and progression of certain cancers, particularly when used in combination with 
existing therapies (AlMatar et al., 2017). Vitamin D insufficiency has recently been 
associated with ovarian cancer (Toriola et al., 2010). Laboratory and genetic studies 
demonstrate promising anticarcinogenic properties of vitamin D, whereas results of 
observational and human studies assessing vitamin D supplementation for the 
prevention of cancers have been inconsistent. Recently reported findings from major 
clinical trials have reported no cancer protection from vitamin D supplementation 
(Brown, 2019). A randomized, double-blind, placebo-controlled trial (the Vitamin D 
Assessment study, ViDA) evaluating the potential efficacy of monthly high-dose 
vitamin D supplementation in reducing the incidence and intermediate outcomes of 
several chronic and acute diseases showed no beneficial effect on cancers (Scragg, 
2019). No official institutional guidelines recommend vitamin D supplementation 
for cancer prevention (McNamara and Rosenberger, 2019).  
An UVB – vitamin D – cancer hypothesis proposing that reduced cancer 
incidence at lower geographical latitudes is related to high levels of vitamin D from 
UVB exposure is also controversial (Brown, 2019). There may be an association 
between BC risk, menopausal status and vitamin D levels according to a pooled 
analysis of two RCTs and one prospective cohort study that showed an 82% lower 
BC incidence rate with serum 25(OH)D levels above 150 nmol/L compared to <50 
nmol/L (McDonnell et al., 2018). Vitamin D receptor polymorphisms may affect the 
risk and mortality of BC, although the role of vitamin D receptors in cancer etiology 
is still equivocal (McNamara and Rosenberger, 2019), and claims of vitamin D 
health benefits are ahead of the evidence. 
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3 Aims 
Vitamin D insufficiency, EBV infection and smoking have been identified as risk 
factors for MS, but it is not known when the risk begins nor when intervention with 
these risk factors would be beneficial. There is some evidence of beneficial effects 
of vitamin D supplementation in the treatment of MS, but with the exception of 
interferons, little is known about whether vitamin D supplementation can be useful 
as an add-on treatment to other DMTs such as fingolimod. Smoking is not only a 
risk factor for MS but also for cancers. Most studies so far investigating the 
association between cancer and MS have suggested a reduced risk of overall cancer 
that is not altered by long-time exposure to injectable DMTs. Cancer risk among MS 
patients in Finland has not been studied in the era of DMTs. The specific aims of this 
study were: 
1. To assess whether serum 25(OH)D levels in early pregnancy are associated 
with future risk of MS in women in the Finnish Maternity Cohort (FMC) 
(Original article II) and their offspring (Original article I). 
2. To determine whether smoking during pregnancy is associated with future 
risk of MS in women in the FMC (Original article III).  
3. To study whether serum EBV antibodies in early pregnancy are associated 
with the risk of MS in women and their offspring in the FMC (Original 
article III).   
4. To study whether vitamin D supplementation in addition to fingolimod has 
a beneficial impact on the clinical course, MRI and safety outcomes as an 
add-on treatment in MS patients in the Phase 3 fingolimod trials (Original 
article IV). 
5. To assess the risk of cancer among MS patients from a prevalence cohort in 
the hospital district in southwestern Finland from year 2004 to 2012 
compared to non-MS patients from the same hospital district (Original 
article V). 
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This work consists of three separate Studies (1-3). The Original articles I-III are 
based on Study 1, and the Original articles IV and V are based on Studies 2 and 3, 
respectively. 
Study 1, Original article I-III. The FMC Study investigated the risk of MS 
association with serum 25(OH)D, EBV antibodies and cotinine levels among women 
and offspring to women in the cohort with a pregnancy serum sample in the FMC, 
which is a nationwide biorepository of serum samples collected during the first and 
early second trimester of pregnancy for routine prenatal testing since 1983. 
Study 2, Original article IV. Pooled data from phase 3 FREEDOMS trials was 
analyzed post hoc to evaluate whether patients in the Phase 3 fingolimod trials using 
vitamin D supplements have better clinical, MRI and safety outcomes than non-
users. 
Study 3, Original article V. This observational nested case-control population 
based study assessed the cancer risk among Finnish MS patients in a hospital district 
cohort from southwestern Finland during the DMT era from January 1, 2004, to 
December 31, 2012, compared to a randomly chosen 10-fold control population of 
non-MS patients from the same hospital district matched by year of birth and gender 
by using hospital administrative data and chart review for case confirmation. 
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4 Materials and Methods 
4.1 Setting 
Finland is geographically located at latitudes of 60°N and 70°N, and is a high-risk 
region for MS. The prevalence differs from 100 to nearly 300 per 100,000 inhabitants 
in different areas, with foci of high prevalence in Ostrobothnia and southwestern 
Finland (Sumelahti et al., 2001, 2003; Sarasoja et al., 2004; Krökki et al., 2011; 
Holmberg et al., 2013; Pirttisalo, Soilu-Hänninen and Sipilä, 2019). In southwestern 
Finland, the age-standardized prevalence to European standard population is 
280/100,000 and the incidence is 12.1/100,000, which are among the highest in 
Finland and globally very high. The female to male ratio in western Finland has 
increased from 2.2 to 2.7 since the 1990s and the mean age of the MS population has 
increased over the same period from less than 40 years to over 50 years (Sumelahti 
et al., 2014; Pirttisalo, Soilu-Hänninen and Sipilä, 2019). In the aging population 
with MS, comorbidities such as cancer play a growing role. In Finland, a total of 
250,000 people had had cancer at some point in their lives in 2011 and there were 
30,000 new diagnosed cases. Cancer becomes more common with increasing age 
and the annual number of cancer deaths among Finns has remained stable around 
11,700, with pulmonary cancer as the most common cause of cancer death. The most 
common cancer in women is BC (n = 4,900) and in men prostate cancer (n = 4,700) 
(Pukkala and Rautalahti, 2013; The Finnish Cancer Registry, 2019). A moderate to 
severe vitamin D deficiency is displayed in almost half of newly diagnosed Finnish 
MS patients, and a high rate of vitamin D insufficiency has previously been reported 
among pregnant, non-MS Finnish women (71%) regardless of their vitamin D intake 
meeting current Nordic recommendations  (10 ug daily) (Viljakainen et al., 2010).  
Specialized medical care is organized by hospital district, distributed between 20 
hospital districts in mainland Finland, each of which belongs to one of the five 
university catchment areas. The patient registers of Turku University Hospital, 
which is the central hospital of the Southwest Finland hospital district covering a 
population of 472,139 people on January 31, 2012, contains clinical data on all 
patients that have visited public hospitals in the district from 2004 onwards. This 
patient register covers practically all patients with MS and cancers requiring 
specialized medical care in the hospital district. 
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In Finland, there are various registers of public health care that ensure 
outstanding coverage of patients with MS. The hospital Discharge Register with its 
continuation, The Care Register for Health Care, contains data on all patients that 
have been admitted to specialized inpatient care, undergone day surgery, or visited 
specialized outpatient care in the country. Annually, data retrieved from the 
electronic client and patient record systems of health care units are submitted to the 
National Institute for Health and Welfare. Finnish residents are eligible for 
reimbursement of medical expenses under the Health Insurance Act. The Social 
Insurance Institutions registry tracks reimbursement recipients, including patients 
with self-administered disease modifying treatments for MS. 
The Finnish Maternity Cohort (FMC) is a nationwide biorepository of serum 
samples established in 1983 and situated in Biobank Borealis at Oulu University 
Hospital since 2017. The biobank serum samples are collected from women during 
the first or early second trimester of pregnancy for routine prenatal testing and 
contains a collection of approximately 2.0 million samples from more than 850,000 
women covering ∼98% of all pregnancies since the FMC establishment. 
4.2 Subjects and methods 
4.2.1 Finnish Maternity Cohort study (Study 1, Original 
Articles I–III) 
The FMC Study is a prospective, nested case-control study conducted in May 2011 
that investigated the risk of MS among the women and offspring of the women with 
a serum sample (date of sample during first or early second trimester of pregnancy, 
5th to 95th percentile: months 2-4 of pregnancy) in the FMC biobank. Samples were 
collected for routine prenatal testing at local maternity care units. Blood samples 
remaining after routine screenings are stored at -25°C in a protected biorepository at 
the Northern Finland Biobank Borealis in Oulu, where they are available for 
scientific research.  
I Vitamin D Status During Pregnancy and Risk of Multiple Sclerosis in 
Offspring of Women in the Finnish Maternity Cohort 
II 25-Hydroxyvitamin D deficiency and risk of MS among women in the 
Finnish Maternity Cohort 
III Epstein-Barr virus and multiple sclerosis risk in the Finnish Maternity 
Cohort.  
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4.2.1.1 Subjects 
Women with MS were identified by linking the FMC database to the Finnish 
Hospital Discharge Register (FHDR, or HILMO), which includes both inpatient 
(since 1967), outpatient neurologic visits (since 1998) and patients in longer-term 
care institutions (since 1994). Diagnostic codes for MS or related disorders (ICD-10 
codes G35, G36, H46, ICD-9 and ICD-8 codes 340, 341, 367, 377) were searched 
for between 1983 and 2009. The majority of Finnish MS patients are diagnosed by 
neurologist evaluation at an inpatient clinic. To identify cases not in the HILMO, the 
FMC database was also linked with the registry of the Social Insurance Institution 
of Finland (SII, or Kela) to search for recipients of prescription drug reimbursements 
for MS DMTs that are admitted based on certificates issued by a doctor confirming 
the MS diagnosis. In the FMC, we identified 1,264 female MS cases listed in HILMO 
or Kela. For 1,252 of these, we had either a medical record or Kela confirmation of 
the diagnosis. For 612 women, medical records were available and reviewed and all 
but 5 of them were clinically confirmed, by Poser criteria for cases occurring prior 
to 2001 and by the McDonald criteria for cases from 2001 to 2009. The remaining 
640 women without available medical records were listed by the Kela registry as 
DMT receivers. The earliest diagnosis date recorded in HILMO, Kela or the medical 
records was set as the date of MS diagnosis. The date of MS onset was available only 
for cases confirmed by medical record review and this date was used as the index 
date to identify serum samples in the FMC collected prior to MS onset, whereas the 
date of diagnosis was used for the Kela-confirmed cases. MS patients were matched 
to up to 3 controls on date of birth (±2 years) and area of residence (by postal code). 
From pregnancies occurring prior to diagnosis, from 1 to 3 serum samples were 
available, and a total of 6,200 serum samples from 1,092 cases and 2,123 controls. 
For 511 cases and 831 controls, ≥2 samples were available.  
Cases of MS among children born to women in the FMC between January 1, 
1983, and December 31, 1991, were identified by HILMO and Kela searches as 
described for the women. Mothers of individuals with a confirmed MS diagnosis 
were identified through over-generation linkage via the Population Census Register. 
Mothers were then linked to the FMC database by their personal identification 
number. Child-mother pairs with available serum samples from the pregnancy were 
included in the study. Medical charts of the children were then reviewed, and MS 
diagnosis was confirmed by study neurologists. MS was confirmed and a maternal 
serum sample available for 193 children (138 confirmed by medical record review 
and 55 by the reimbursement/prescription of MS DMTs) and up to 2 matched 
controls were found for 176 of them (for 17 cases a suitable control could not be 
identified). Controls were matched by region of birth (south, southwest, southeast, 
middle and north), date of maternal sample collection (±60 days), date of mother’s 
birth (±6 months) and date of offspring birth (±2 months). The total number of 
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controls was 326. There were an additional 5 controls that were selected but 
ultimately not matched. 
4.2.1.2 Laboratory analyses 
FMC serum samples of 1-3 ml volume remaining after routine prenatal screenings, 
previously processed and stored in the Finnish National Institute for Health and 
Welfare in Oulu, are since 2017 stored at -25°C at the Borealis Biobank in Oulu.  
25-hydroxyvitamin D (Original article I-III) 
Serum 25(OH)D levels were measured in all pre-diagnostic case and control samples 
for the women and in maternal samples for offspring cases and controls in the FMC 
using a chemiluminescence microparticle immunoassay and an Architect i2000SR 
automatic analyzer (AbbottDiagnostics).   
Cotinine (Original article III) 
Serum cotinine, the biomarker for cigarette smoking, was measured using a 
commercially available quantitative immunoassay kit (OraSure Technologies, 
Bethlehem, PA, USA) (sensitivity=96-97%, specificity=99-100%).  Intra- and inter-
assay variation are 3.5-6.2%, and 6.0-9.6%, respectively.  The limit of detection was 
0.08 ng/ml.  Women were considered non-smokers if their cotinine levels were <10 
ng/ml and smokers if their cotinine levels were >25 ng/ml.  Cotinine levels of ≥10 
ng/ml and ≤25ng/ml were considered equivocal and were categorized separately. 
EBV and CMV IgG measurement (Original article III). 
For the offspring analysis, maternal IgG antibodies to the EBV antigens VCA, 
EBNA-1, EA-D and to CMV were measured using an enzyme-linked 
immunosorbent assay (ELISA) according to manufacturer’s instructions (DiaMedix 
Corp., Miami, FL). For the analysis among the FMC women, only serum EBNA-1 
IgG antibodies were measured because these antibodies were the strongest predictors 
of MS risk in previous prospective studies. Samples were positive for EBV IgG 
antibodies if the ELISA index value was ≥1.10 and negative if the index value was 
<0.90.  Index values in between were equivocal.  For CMV, index values of <8.0 
were negative, ≥10 were positive, and 8.0-9.99 were equivocal. Quality control 
samples were included among the study samples and coefficients of variation ranged 
from 3.1% (VCA) to 8.2% (EA-D).   
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4.2.1.3 Statistics 
Original article I. All analyses were done using SAS v9.3. (SAS Institute Inc). The 
25(OH)D levels were modeled (1) as a continuous variable, (2) as quintiles based on 
the distribution of maternal 25(OH)D levels in the controls, and (3) as a priori 
categories consistent with deficient (<30 nmol/l), insufficient (30 to <50 nmol/l) and 
sufficient (≥50 nmol/l) levels. Conditional logistic regression was used in the main 
analysis to estimate the rate ratios and 95% CIs and included 176 cases with 326 
matched controls. Analyses were further adjusted for the sex of the child, gestational 
age at sample collection and season (summer, winter, or spring/fall) of sample 
collection. In secondary analyses, an unconditional logistic regression adjustment 
was performed for all of the matching factors in all 193 cases and 331 controls and 
stratified by sex of the child (female: 163 cases and 218 controls; male: 30 cases and 
113 controls). A p-value of less than 0.05 was considered statistically significant. 
Original article II. Main analysis included 1,092 cases and 2,123 controls. For 
women with several 25(OH)D measurements, levels were averaged as an estimate 
of their longer term 25(OH)D exposure and modeled as described above. In addition 
to matching factors (age and residence), multivariate models were adjusted for time 
of sample collection (number of samples collected during or after the 2004 
recommendation of vitamin D supplement for pregnant women), gravidity (1, 2, ≥3) 
and parity (0, 1, ≥2). The missing indicator method was used to model gravidity and 
parity for women missing information on these covariates in order to retain all 
observations in the analyses. Tests for linear trends across the categories and 
quintiles were conducted by assigning the median 25(OH)D value for each 
category/quintile to all cases/controls in that category and modeling the median 
25(OH)D as a linear variable. In sensitivity analysis, we restricted to MS cases with 
clinical confirmation (i.e. medical record review) of MS (n = 604) and cases with 
multiple 25(OH)D measurements from multiple pre-diagnostic pregnancies (n = 
511) and their matched controls. To evaluate seasonal variation of 25(OH)D and MS 
association, samples were categorized by month of collection into months of high 
UV light (May – October, n = 800 cases/1,740 controls) and low UV light 
(November – April, n = 764 cases/1,677 controls). Women with samples collected 
in both high and low UV months will be in both analyses, and we averaged 25(OH)D 
levels for women with several samples collected within the high or low UV month 
period. Unconditional regression adjusting for age, geographic location and other 
factors listed above, was used to estimate relative risks (RRs) and 95% CIs 
associated with 25(OH)D 50 nmol/L increases in the UV-specific analysis.  
Original article III. SAS v9.4 was used to conduct the statistical analysis, and 
the approach was similar in women and offspring. EBV IgG antibody analyses were 
restricted to the offspring of EBV positive women with at least one matched EBV 
positive control (FMC women: 1,049 MS cases and 1,867 controls; offspring: 170 
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MS case mothers and 311 control mothers) and analyses of CMV IgG antibodies 
were restricted to CMV positive matched case/control groups (offspring: 116 MS 
case mothers and 177 control mothers). The index values for IgG antibodies against 
the EBV and CMV antigens were standardized to control values and modeled as 
continuous variables and quintiles determined based on the distribution of the 
standardized IgG index value for each antigen among the controls. Consistent with 
the matched design, conditional logistic regression was used to estimate the relative 
risks and 95% CIs. In the offspring analysis, models were adjusted for offspring 
gender, gestational age at sample collection, and maternal cotinine and 25(OH)D 
levels (<30 nmol/L, 30-50, >50) previously measured in these samples (original 
article I, data not shown). In the analysis among women, models were adjusted for 
parity and gravidity (as previously described), and previously measured 25(OH)D 
and cotinine levels (original article II, data not shown). Trend p-values for the 
quintile analyses were calculated by modeling the median IgG antibody index value 
for each quintile as a continuous variable. Sensitivity analyses were conducted by 
restricting to EBV positive cases of MS confirmed by medical record review (FMC 
women n = 588; offspring n = 138) and matched controls. 
4.2.2 Fingolimod and vitamin D study (Study 2, Original 
article IV) 
This study assessed the effect of vitamin D supplement use on clinical, MRI, and 
safety outcomes by a post hoc analysis of pooled data from the phase 3 FREEDOMS 
pivotal fingolimod trial patients compared to casual and no use of vitamin D.  
4.2.2.1 Subjects 
This was a post hoc analysis of pooled data from the Phase 3 FREEDOMS I and II 
trials (Kappos et al., 2010; Calabresi et al., 2014). Data on use of multivitamins and 
vitamin D were retrieved from the “Concomitant Medications” section of the 
electronic case report forms. Vitamin D users were defined as those on concomitant 
vitamin D supplementation during the core study period, whereas patients using 
multivitamins were not considered vitamin D users unless they also took vitamin D. 
Patients (n = 1,953) were categorized into 3 groups: 
1) Daily users: daily supplemental vitamin D use 100% of the time during 
the study (n = 120) 
2) Casual users: supplemental vitamin D use <100% of the study time (n = 
170) 
3) Non-users: no use of supplemental vitamin D (n = 1,663) 
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The analysis was limited to patients from countries where the use of vitamin D was 
prominent (USA, n = 731; Canada, n = 74; Australia n = 24)(daily users n =110, 80% 
female; casual users n = 157, 80.9% female; non-users n = 562, 74.7% female; total 
n = 829). Vitamin D supplement use in other countries was very limited. 
4.2.2.2 Evaluated outcomes 
Clinical outcomes were evaluated by aggregate ARR up to month 24 (M24), 
proportion of patients with confirmed relapse at month 12 (M12) and M24 and EDSS 
change from baseline to M24. Safety was evaluated by AE reporting, including 
depression (no scale or questionnaire or assessment tool for depression was used 
separately). 
MRI outcomes were evaluated by numbers of new/newly enlarged T2 lesions 
from baseline to M12 and M24, proportion of patients free of these changes at M12 
and M24, number of Gd-enhancing T1 lesions at M12 and M24 as well as proportion 
pf patients free of these findings at M12 and M24. Percent brain volume change 
(PBVC) was evaluated from baseline to M12 and 24. Safety was evaluated by 
incidence of infections and depression. 
4.2.2.3 Statistics 
Baseline characteristics were compared using the Wilcoxon test for quantitative 
variables and the Chi-square trend test for categorical variables (electronic case 
report forms, eCRF). Various generalized linear models were adjusted for treatment, 
vitamin D use, baseline, age, region and treatment - vitamin D use interaction. The 
ARR at month 24 by vitamin D use was studied using a negative binominal 
regression model adjusted for treatment, vitamin D use, number of relapses in the 
previous 3 years, baseline EDSS, and region. MRI outcomes by vitamin D use were 
calculated from a Rank ANCOVA or logistic regression model with the following 
covariates: treatment, vitamin D use, region, baseline volume or number of lesions, 
and treatment-vitamin D use interaction. In the evaluation of MRI outcomes by 
treatment within vitamin D subgroups, report was made at the group level (pair-wise 
comparisons) due to the small number in each of the vitamin D subgroups. 
4.2.3 MS and cancer risk study (Study 3, Original article V) 
The study on cancer risk among Finnish MS patients was a population-based nested 
case-control study assessing cancer risk among MS patients and a non-MS patient 
10-fold control population in a hospital district cohort from southwestern Finland 
during a period from January 1, 2004, to December 31, 2012. 
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4.2.3.1 Subjects 
Patients with ICD-9 (3400A) and ICD-10 (G35) codes for MS were searched for 
from the hospital administrative data in the Southwest Finland hospital district from 
January 1, 2004 to December 31, 2012, as described previously (Åivo et al., 2017; 
Murtonen et al., 2018). A total of 1,074 confirmed MS cases (70.7% female, n = 
759; 29.3% male, n = 315) were treated in the hospital district, including the 
deceased cases (5.9%, n = 70) after January 1, 2004. Cancers in the MS cohort and 
control group were searched for by ICD-10 codes C00-C96. Cancers diagnosed both 
before and after the date of definite MS diagnosis were included. The control 
population was a 10-fold population (n = 10,740) with the same gender and year of 
birth, randomly selected from the Turku University Hospital patient register. 
Another separate control population from the same patient pool was used to verify 
the stability of the results. A total of 818 patients in the summoned MS and control 
cohorts were diagnosed with cancer (mean age 58.8 years). 68 cancer cases were 
found in the MS cohort and after adjusting for multiple cancers in part of the subjects, 
a total of 61 MS patients with cancer comorbidity and 757 controls with cancer 
remained. 
ORs and 95% CIs were calculated for the overall risk of cancer and for the risk 
of specific cancer types in the cohorts. Patient documents of the confirmed MS cases 
with diagnoses of cancers were reviewed to assess disease type, smoking habits, 
alcohol use, profession, use of vitamin D supplements, BMI, parity, family history 
of cancers and MS, first symptom of MS, first symptom or sign of cancer, received 
cancer treatments (surgery, radiation and chemotherapy), other surgery, EDSS, the 
use of MS therapies, use of other medications including hormonal replacement 
therapies, type of cancer or cancers and the outcome of cancer. The causes of all 
deaths during the study period were obtained by review of the patients’ charts as 
described previously (Murtonen et al., 2018). 
4.2.3.2 Statistics 
The ORs were calculated with 95% CIs and p-values were calculated using Pearson’s 
χ2 test. Age at BC diagnosis was compared between groups using the ANOVA test. 
All statistical tests were two-tailed and p-values less than 0.05 were considered 
statistically significant. Statistical analyses were performed using R Statistics 
version 3.0.2 with standard packages. Kaplan-Meier (KM) analysis was performed 
for cumulative incidence proportion and age (years) at BC diagnosis for MS and year 
of birth- and gender-matched controls. Significance was assessed by log-rank test. 
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4.2.4 Ethical aspects 
Study 1, Original articles I-III. There is a legal basis for the collection and scientific 
use of the FMC (The law of the National Institute for Health and Welfare 828/1981, 
327/2001 and 668/2008668/2008). An informed consent system based on the opt-
out principle has been in operation nationwide in Finland since 2001. The FMC study 
was approved by the data protection authorities at the National Institute for Health 
and Welfare (THL), the Regional Ethics Committee of the Northern Ostrobothnia 
Hospital District and by the Office of Human Research at the Harvard T.H. Chan 
School of Public Health. Before year 2001 no informed consent was needed, but 
since year 2001, informed consent of the women was obtained for serum sample 
storage at the biobank for research purposes. 
Study 2, Original article IV. In the fingolimod and vitamin D supplement study 
no further written consents were required since there was no direct contact with the 
patients in the data mining pool. The previous FREEDOMS studies were performed 
in accordance with ethical standards laid down in the 1964 Declaration of Helsinki 
and its later amendments. All persons included in these study trials had given their 
informed consent prior to inclusion in the studies.  
Study 3, Original article V. This was a register study and no written consents 
were required since there was no direct contact with the patients. The study was 
performed in accordance with the code of ethics of the World Medical Association, 
i.e. ethical standards laid down in the 1964 Declaration of Helsinki and its later 
amendments. The study was registered and approved by the Turku Clinical Research 
Center (Turku CRC) and ethical committee approval was obtained from the joint 
Ethics Committee of Tampere University and the Pirkanmaa Hospital District.  
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5 Results 
5.1 Finnish Maternity Cohort study (Study 1, 
Original publication I–III) 
5.1.1 Vitamin D and risk of MS among offspring (I) 
In this prospective, nested case-control study conducted in May 2011, mean age at 
offspring MS diagnosis was 19.8 years (SD 3.2), a low average age as a consequence 
of the study period since establishment of the FMC in 1983. The cases and controls 
did not differ in terms of the mother’s age, gestational age, and the serum sample 
collection season. No cases and 2 controls had a mother with MS. Of the 193 
offspring MS cases, 163 were female. There were more women in the offspring case 
group (84% versus 66% among controls). Serum samples were collected during the 
first trimester (70%) and early second trimester (99% prior to 28 weeks’ gestation). 
Mean 25(OH)D levels did not differ according to the trimester of sample collection 
(first trimester 36.59 nmol/L, second trimester 36.19 nmol/L). The maternal serum 
25(OH)D average level was 34.59 nmol/L (8.74 – 160.49 nmol/L) for offspring cases 
and 37.49 nmol/L in mothers of controls. Only 2 cases and 8 controls had maternal 
25(OH)D levels of >75 nmol/L and no cases and 1 control had maternal 25(OH)D 
seral levels of >99.9 nmol/L. A 50 nmol/L increase in the maternal 25(OH)D level 
was associated with a 48% reduced risk of MS in offspring in the matched analysis 
(adjusted for gender, gestational age and season at time of sample collection), 
although this finding did not reach  statistical significance (relative risk [RR] 0.52, 
95% CI 0.22–1.19, p-value 0.12). Children of mothers with deficient 25(OH)D had 
an increased risk of developing MS compared to children of non-deficient mothers. 
In multivariate analyses using 25(OH)D a priori categories, clearly deficient 
maternal levels were associated with an almost 2-fold increased MS risk in the child 
(<30 nmol/L versus 30 to <50 nmol/L, RR 1.90, 95% CI 1.20–3.01, p-value 0.04). 
Maternal 25(OH)D levels in the bottom quintiles 1 and 2 (<31.50 nmol/L) were 
associated with a 20% to 90% increased offspring MS risk compared to maternal 
levels in the top quintile (median 56.21 nmol/L, p trend 0.09). 
In the unmatched analysis, a 43% reduced risk of MS was associated with every 
10.00 nmol/L increase in maternal 25(OH)D level (RR 0.57, 95% CI 0.28–1.18, p-
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value 0.13) and a 59% increased risk of MS among offspring to vitamin D deficient 
mothers (<30 nmol/L versus 30 to <50 nmol/L, RR 1.59, 95% CI 1.04–2.42, p-value 
0.03). In analyses stratified by child gender this association was only evident in 
female offspring (<30 nmol/L versus 30 to <50 nmol/L, RR 1.75, 95% CI 1.09–2.81, 
p-value 0.02). 
MS risk was 90% higher (nearly 2-fold increased risk) in offspring of vitamin D 
deficient mothers (serum 25[OH]D <30 nmol/L) compared to offspring of mothers 
who were not deficient (RR 1.90, 95% CI 1.20–3.01, p-value 0.006), a statistically 
significant difference supporting the role of prenatal vitamin D in determining MS 
risk and suggesting that correction of vitamin D deficiency during pregnancy may 
reduce the risk of MS in offspring.  
5.1.2 Vitamin D and risk of MS among women (II) 
An expected seasonal distribution of 25(OH)D levels among the FMC women was 
exhibited (with increasing levels towards summer and decreasing levels towards 
winter months), but with remarkably stable averages from 1983 until 2004 (when 
Finland formally recommended that pregnant women take vitamin D supplements). 
The average pre-diagnostic 25(OH)D serum levels were 1.3 nmol/L lower among 
women who developed MS compared to controls. Among cases and controls >50% 
had deficient levels (<30 nmol/L) and in both groups over one third had insufficient 
levels (30 to <50 nmol/L). There were only 6 cases and 9 controls with serum 
25(OH)D levels of ≥75 nmol/L, and of these only 1 case and 2 controls had levels of 
≥100 nmol/L. There was an average of 9.5 years between first sample collection and 
the recorded date of MS diagnosis among 604 MS cases with medical record 
confirmation. 
In multivariate-adjusted analyses including all cases and controls, a 25(OH)D 50 
nmol/L increase was associated with a 39% reduced MS risk (adj RR 0.61, 95% CI 
0.44–0.85, p-value 0.003). Deficient women had a 43% increased MS risk compared 
to women with 25(OH)D serum levels of ≥50 nmol/L, and a 27% increased risk 
compared to women with insufficient levels of 30 to <50 nmol/L (adj RR 1.27, 95% 
CI 1.07–1.50, p-value 0.005). 
In quintile analyses, women with extreme 25(OH)D deficiency (bottom 2 
quintiles <26.8 nmol/L) had a 53-66% increased MS risk compared to women in the 
25(OH)D top quintile (≥41 nmol/L), and there was a statistically significant overall 
trend of increasing MS risk with decreasing 25(OH)D (p-value <0.0001). In the 
analyses stratified by season of sample collection, similar inverse associations 
between serum 25(OH)D and MS risk were observed. The RR associated with a 50 
nmol/L increase when using serum samples collected in high UV months May – 
October was 0.71 (95% CI 0.52–0.91, p-value 0.02) and for serum samples collected 
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in low UV months November – April, RR was 0.65 (95% CI 0.43–0.98, p-value 
0.04). In analyses restricted to 511 MS cases and controls with ≥2 samples prior to 
diagnosis, risk estimates were stronger with a 50 nmol/L 25(OH)D increase 
associated with a 41% reduction of MS risk (adj RR 0.59, 95% CI 0.34–1.03, p-value 
0.07) and levels of <30 nmol/L with a 2-fold increase in MS risk as compared to 
levels of ≥50 nmol/L. In quintile analyses, women in the 2 bottom quintiles (Q1-Q2) 
with serum 25(OH)D levels of <26.8 nmol/L had a 37% - 87% increased risk of MS 
compared to women in the top quintile of ≥41 nmol/L (Q1 versus Q5: RR 1.37, 95% 
CI 0.89–2.12; Q2 versus Q5: RR 1.87, 95% CI 1.25–2.79, p trend 0.03), with similar 
results among women with MS confirmed by medical record review and their 
matched controls. 
5.1.3 EBV and risk of MS in women and offspring (III) 
In offspring analyses, 70% of maternal samples were collected during the first 
trimester of pregnancy and 98.3% and 97.8% of mothers of cases and controls, 
respectively, were positive for EBV infection, whereas similarly 79.6% and 73.4% 
of case-control mothers were positive for CMV infection. Maternal seropositivity to 
EBV and CMV was not associated with offspring MS risk increase (EBV: RR 1.28, 
95% CI 0.32–5.21, p-value 0.73; CMV: RR 1.39, 95% CI 0.87–2.22, p-value 0.17). 
No statistically significant associations were observed after adjusting for offspring 
gender, gestational age at sample collection, cotinine and 25(OH)D levels (EBV: RR 
0.74, 95% CI 0.17–3.19, p-value 0.68; CMV: RR 1.23, 95% CI 0.74–2.03, p-value 
0.43). 
A one standard deviation increase in maternal VCA IgG index value was 
associated with a 34% increased offspring MS risk (RR 1.34, 95% CI 1.07–1.67, p-
value 0.01). After adjusting for the factors described, the results remained mainly 
unchanged (RR 1.41, 95% CI 1.11–1.80, p-value 0.006). In quintile analyses, 
children of mothers in the highest VCA IgG index value quintile had a 2-fold 
increased risk of MS occurrence (RR 2.01, 95% CI 1.05–3.86, p trend 0.01), a strong 
association that remained after adjusting for offspring gender, gestational age at 
sample collection, maternal 25(OH)D and cotinine levels (RR 2.44, 95% CI 1.20–
5.00, p trend 0.004). No associations were seen with a one standard deviation 
increase in maternal EBNA-1-, EA-D- or CMV IgG index values and offspring MS 
risk either without or with adjustment for offspring gender, gestational age at sample 
collection and maternal 25(OH)D and cotinine levels or in quintile analyses. 
The Pearson correlation coefficients between maternal EBV IgG and 25(OH)D 
levels were: VCA 0.01; EBNA-1 -0.04; EA-D 0.05; CMV 0.08. After adjustment for 
EBV IgG levels and cotinine, maternal deficient 25(OH)D levels <30 nmol/L, as 
compared to levels of 30-50 nmol/L, remained statistically significantly associated 
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with a nearly 2-fold increased MS risk in the offspring (adjusted for VCA IgG: RR 
1.95, 95% CI 1.20–3.17, p-value 0.007; adjusted for EBNA-1 IgG: RR 1.98, 95% CI 
1.23 –3.19, p-value 0.005; adjusted for EA-D: RR 1.97, 95% CI 1.23–3.16, p-value 
0.005). There was no statistical interaction between the maternal EBV IgG and 
25(OH)D or cotinine levels and MS risk in the offspring, and the results remained 
materially unchanged after restricting the analysis to the 124 cases with medical 
record review confirmation of MS and 225 matched controls. 
Among the FMC women, there were 1,049 MS cases and 1,867 controls that 
were EBV seropositive prior to MS diagnosis. The mean age at MS diagnosis was 
37 (SD 7.1) and the mean age at sample collection was 27.6 (5.1) for cases and 27.6 
(5.1) for controls. The mean EBNA-1 IgG index among cases and controls were 4.60 
(0.50) and 4.37 (0.70), respectively. The mean levels for 25(OH)D among cases and 
controls were 29.6 (12.2) and 31.0 (13.3), whereas the mean levels for cotinine 
(ng/ml) for cases and controls were 35.8 (79.8) and 28.0 (69.6), respectively. Serum 
samples were collected an average of 9.4 years prior to MS diagnosis, and 10.4 years 
prior to diagnosis for clinically confirmed cases, for whom the date of MS onset was 
available.  
Notably, women who developed MS had higher mean pre-onset serum cotinine 
levels than the controls (35.8 ng/ml versus 28.0 ng/ml, and cotinine levels indicative 
of recent smoking were observed in 24.5% of cases versus 19.7% of controls). 
Women with cotinine levels of >25 ng/ml (smokers) had a 45% increased risk of MS 
as compared to women with cotinine levels of <10 ng/ml (non-smokers) (RR 1.45, 
95% CI 1.19 – 1.17, p-value 0.0002), the results were mainly unchanged after 
adjusting for EBNA-1 index values, parity, gravidity, and 25(OH)D levels (RR 1.50, 
95% CI 1.21 – 1.85, p-value 0.0002).  
In the available pre-onset samples, 99.3% of the 1,053 women who developed 
MS and 97.7% of the 1,892 controls were seropositive for EBV, yielding a nearly 
3.5-fold increased MS risk associated with EBV seropositivity (RR 3.44, 95% CI 
1.55–7.66, p-value 0.003). After adjusting for parity, gravidity, serum 25(OH)D and 
cotinine levels, RR was 3.54 (95% CI 1.56–8.02, p-value 0.0024).  
A one standard deviation increase in EBNA-1 index value levels in pre-onset 
samples was associated with an increased risk (RR 1.61, 95% CI 1.44–1.80, p-value 
1.11e-16) with similar results after adjusting for parity, gravidity, 25(OH)D and 
cotinine levels (RR 1.57, 95% CI 1.40–1.76, p-value 2.22e-15). 
In quintile analyses as EBNA-1 IgG index levels increased, there was an increase 
in MS risk (RR top versus bottom quintile 3.42, 95% CI 2.56–4.56, p trend <1.11e-
16), an association that persisted after adjusting for factors previously described. 
The previously observed (original article II) increased risk of MS among women 
with deficient 25(OH)D levels as compared to women with sufficient levels persisted 
after adjusting for EBNA-1 IgG and cotinine (RR1.41, 95% CI 0.99–2.01, p-value 
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0.06) and results were not changed by restriction to cases with medical review 
confirmation of MS. Serum EBNA-1 IgG index value and 25(OH)D levels were not 
correlated (r -0.003). 
Among women in the FMC, those with the highest versus lowest quintile of 
EBNA-1 IgG levels had a 3-fold higher risk of MS (RR 3.21, 95% CI 2.37–4.35, p 
trend <1.11e-16). In conclusion, smoking increases the risk for MS in the smoking 
subject and offspring of mothers with high VCA IgG during pregnancy appear to 
have an increased risk of MS, and the increase in MS risk among women with 
elevated pre-diagnostic EBNA-1 IgG levels is consistent with previous results. The 
EBV-associated MS risk in mothers and offspring was not confounded or modified 
by 25(OH)D or cotinine levels. 
5.2 Fingolimod and vitamin D supplement (Study 
2, Original publication IV) 
Within the study population, ARR after two years was significantly lower in the 0.5 
mg fingolimod group compared to placebo (0.188 and 0.370, respectively; p-value 
0.0004). No difference in ARR was observed between the vitamin D supplement 
user groups, nor did the proportion of patients with relapses differ between vitamin 
D ´daily´, ´casual´ or ´non-users´ at M12 and M24. The EDSS change from baseline 
for two years was minimal and did not differ between the vitamin D ´ daily´ and ´ non-
user´ groups (p-value 0.262). The fingolimod treatment effect compared to placebo 
was seen in all subgroups, but the small sample size makes it impossible to conclude 
a treatment effect between the vitamin D use subgroups.  
Vitamin D supplement as an add-on therapy to fingolimod had beneficial effects 
on MRI outcomes, such that the proportion of patients free of new/enlarging T2 
lesions significantly favored vitamin D daily versus non-users (M12, p-value 0.038; 
M24, p-value 0.009). The mean numbers of new/enlarging T2 lesions from baseline 
to M12 and M24 were lower in the vitamin D daily user groups compared to non-
users but did not reach statistical significance.  
The proportion of patients free of Gd+ T1 lesions was higher among daily 
vitamin D users compared to non-users at M12 and M24 (whereas there was no 
difference between casual and non-users) and the mean number of Gd+ T1 lesions 
was lower between daily users and non-users at M12 and M24, and also lower for 
casual users at M12 compared to non-users (p-value 0.04). PBVC at M12 was 
significantly lower in the vitamin D daily than non-user group (p-value 0.018) and 
remained low (non-significant) at M24.  
There was a trend of less depression reported as an AE in the daily vitamin D 
supplement user group (5.5%) compared to casual (10.8%) and non-users (11.9%) 
among patients in the FREEDOMS trials. The incidence of infections was similar in 
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all groups, with nasopharyngitis and upper respiratory tract infection being the most 
common. No severe adverse events (SAEs) where seen and safety outcomes did not 
differ from the control group. Our study suggests that there is a basis for 
recommendation of vitamin D supplement not only for patients treated with IFN, but 
vitamin D supplements can also be beneficial when combined with fingolimod 
treatment in MS subjects.  
5.3 MS and cancer study (Study 3, Original 
publication V) 
In the cohort of 1,074 MS patients (70.7% female, 29.3% male), 70 patients (5.9%) 
deceased after January 1, 2004. A total of 818 patients in the summoned MS and 
control cohorts were diagnosed with cancer (mean age 58.8 years). We found 68 
diagnoses of cancer in the MS cohort, and after adjusting for multiple cancers in part 
of the subjects, there were 61 MS patients with cancer comorbidity (5.7%, mean age 
57.3 years) and in the 10-fold control population matched for gender and date of 
birth we found 757 cancer cases (7.0%, mean age 58.9 years)(ANOVA p-value 
0.317). Among the 70 MS patients that deceased during the study period, there were 
a total of 11 cancer cases (5 cases of BC, 3 intestinal cancers, 2 pulmonary cancers 
and 1 thyroid cancer). In only 4.3% of the deceased patients, cancer was the cause 
of death (2 cases of BC and 1 intestinal cancer). Other causes of death were 
respiratory infection (n = 2), unlocalized infections (n = 2) and respiratory 
insufficiency (n = 4).  
The overall risk of cancer among MS patients in our study population of 
southwestern Finland did not differ from the control population (OR 0.80, 95% CI 
0.6–1.0, p-value 0.092). The mean age at cancer diagnosis did not statistically differ 
between the MS and control cohorts (two-tailed t-test p-value 0.317). All BC cases 
were female and age at BC diagnosis was significantly higher among the MS patients 
(n = 18) compared to controls (n = 207) (61.7 vs. 55.7 years, ANOVA test p-value 
0.010) and the risk of BC was slightly lower in the MS group (OR 0.9, 95% CI 0.5–
1.4, p-value 0.566). Among MS patients with BC, 7 subjects had no DMT, 5 had 
received DMT (IFN, of which 3 patients switched to GA) and for 6 data was not 
available (3 cases were defined as PPMS). Only 1 (5.6%) patient had a history of 
smoking, while 8 (44.4%) were self-reported non-smokers and for 50% no data on 
smoking was available. Data on lifestyle and environmental confounding factors 
(e.g. alcohol use, gravidity and parity, BMI, family history of cancer, hormonal 
replacement therapies and vitamin D use) was scarce or missing and no conclusions 
of DMT impact on cancer risk could be made due to the small patient numbers.   
In the MS cohort, we observed a decreased risk for prostate cancer and increased 
risk for oral cavity cancers, colon cancer, lung cancer, renal cancer, brain cancer and 
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thyroid cancer. Among the MS patients with high-odd cancers, DMTs used were 
IFN, GA, natalizumab (n = 1), and one case had participated in a study to receive 
either TRF or placebo, but patient numbers were too small to draw any conclusions 
of statistical significance, neither for cancer risk, nor for DMT risk impact. 
Table 5.  Summary of study findings 
Study 1, original publications I-III   
Maternal serum status impact on MS risk mother offspring 
Vitamin D deficiency (<30 nmol/l) yes♣ yes♦ 
Cotinine (>25 ng/ml, smoker) yes♥  
CMV IgG seropositivity  no♠ 
EBV seropositivity yes♠ no♠ 
VCA IgG index value ↑  yes♠ 
EBNA-1 IgG index value ↑ yes♠ no♠ 
EA-D IgG index value ↑  no♠ 
Study 2, original publication IV   
MS and vitamin D beneficial effect at 
M12/M24 
users M12  
(vs non-users) 
users M24 
(vs non-users) 
Clinical outcome measures (ARR, EDSS) no no 
Radiological outcome measures  
(proportion of patients free of new/ 
enlarging T2 lesions, proportion of 
patients free of Gd+ T1 lesions, lower 
mean number of Gd+ T1 lesions) 
yes yes 
Study 3, original publication V   
Cancer risk MS population vs control 
population 
 
Overall cancer risk OR 0.80 (95% CI 0.6–1.0) p-value 0.092 
ARR = annual relapse rate; EDSS = expanded disability status scale; OR = odds ratio; CI = 
confidence interval; EBV = Epstein-Barr virus; EBNA-1 = EBV nuclear antigen; IgG = 
immunoglobulin G; CMV = cytomegalovirus; VCA = viral capsid antigen; EA-D = early antigen D; M 
= Month. P-value less than 0.05 was considered statistically significant. ♣Unaffected by EBNA-1 
IgG and cotinine levels; ♦Unaffected by EBV IgG and cotinine levels; ♥Unaffected by EBNA-1 index 
values and 25(OH)D levels; ♠Unaffected by cotinine and 25(OH)D levels 
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6 Discussion 
6.1 The Finnish Maternity Cohort study 
6.1.1 Vitamin D levels and risk of MS in women and their 
offspring 
In the FMC study, we found that women with low serum 25(OH)D levels of <30 
nmol/L had a 43% higher MS risk, and for women with ≥2 samples available prior 
to MS diagnosis (511 cases), MS risk was 2-fold higher in those with 25(OH)D levels 
of <30 nmol/L as compared to women with levels of ≥50 nmol/L (repetitive findings 
are less affected by random variations than those based on a single measurement). A 
50 nmol/L increase in 25(OH)D was associated with a 39% reduced risk of MS.  
For the offspring, we showed that maternal vitamin D deficiency in early 
pregnancy was associated with a nearly 2-fold increase in risk of MS in their children 
compared to vitamin D non-deficient mothers.  
It has previously been unclear whether in utero exposure to vitamin D deficiency 
exerts an effect on risk of MS in offspring, with no former published data on the risk 
in the Finnish population, although previous evidence hints this could be the case in 
other populations. A higher intake of vitamin D during pregnancy has been 
associated with a lower risk of MS in offspring (Mirzaei et al. 2011). In the northern 
hemisphere, MS patients are more likely to be born in spring after winter months of 
low sunlight and consequent low levels of 25(OH)D during gestation (Willer et al., 
2005; Torkildsen et al., 2012), whereas the pattern is reversed in the southern 
hemisphere with excess MS births in November and December (Staples, Ponsonby 
et al. 2010). Previous Swedish studies investigating the association between 
25(OH)D serum levels and MS risk found no significant association between 
gestational vitamin D levels and MS in a small cohort of 37 cases (Salzer et al., 
2012), and there was no association between future MS risk and 25(OH)D levels in 
dried blood spot sample levels collected from neonates in another study (Ueda et al., 
2014). The findings may have been altered by degradation of 25(OH)D in older 
samples and lower participation among controls, perhaps whereby the controls might 
not be truly representative of the general population. On the other hand, a large case-
control study including over 500 MS patients and 1,000 controls that assessed 
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25(OH)D levels in neonate dried blood spot samples from the Danish Newborn 
Screening biobank found that a 25 nmol/L increase reduced the risk of MS by 30% 
(Nielsen et al., 2017), which is also in line with our study findings. Previous studies 
have shown that neonatal umbilical cord 25(OH)D levels correlate with maternal 
25(OH)D levels (Godang et al., 2014), suggesting that maternal vitamin D levels are 
an adequate indicator of 25(OH)D levels to which the fetus is exposed. 
The strength of our FMC study is its large size and coverage, including samples 
from about 98% of all pregnancies in Finland since 1983. The risk of selection bias 
is minimized by the excellent coverage of MS patients in Finland for the Hospital 
Discharge Register and Social Insurance Institution register for reimbursement used 
in case selection. Because the FMC was established in 1983, offspring cases of 
mothers in this cohort were young with an average age of 19.8 years at MS diagnosis, 
accompanied by the possibility that the association between gestational vitamin D 
levels and MS risk decreases at older ages. The majority of women in our study had 
deficient levels of vitamin D and further studies will be needed to estimate the 
possible dose-response effect in populations with higher variation in vitamin D 
levels. For the offspring, we did not have information on risk factors for MS such as 
HLA DRB1*1501 status, EBV infection, cigarette smoking, vitamin D levels or 
obesity during childhood or adolescence, but previous work suggests these are not 
major confounders of the vitamin D and MS association, with perhaps obesity being 
an exception (Munger et al., 2011; Mokry et al., 2015, 2016; Rhead et al., 2016). 
Since 25(OH)D levels are likely to correlate between mothers and their children also 
later in life due to shared behavioral factors, e.g. sun exposure and use of vitamin D 
supplementation in addition to shared genetic risk factors, it is possible that the 
increased risk of MS in children born to vitamin D-deficient mothers is a 
consequence of low levels of vitamin D during childhood and adolescence, and 
reverse causation can be debated.  
We found that women from the cohort who were vitamin D-deficient had an up 
to 2-fold increased risk of developing MS, when comparing one or repetitive samples 
with 25(OH)D samples from vitamin D-sufficient mothers. Since previous studies 
suggest historically low vitamin D levels during pregnancy in Finnish pregnant 
women (Viljakainen et al., 2010), we specifically sought to examine whether 
deficient and insufficient 25(OH)D levels during the first and early second trimester 
of pregnancy are associated with an increased MS risk in the mothers. There is much 
evidence supporting a role for adequate vitamin D nutrition in reducing MS risk 
(Ascherio and Munger, 2016). Two previous prospective studies examining whether 
25(OH)D levels in healthy subjects predict future MS risk have found that elevated 
levels of 25(OH)D of ≥75 nmol/L (Salzer et al., 2012) and ≥100 nmol/L (Munger et 
al. 2006) were associated with an approximately 60% decreased risk of later 
developing MS. Both studies included only a few non-Hispanic Caucasian MS 
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subjects and one was not able to directly examine whether deficient vitamin D levels 
were associated with an increased risk of MS, and only 5% of individuals had 
25(OH)D levels below 50 nmol/L (Munger et al. 2006), while the other reported no 
associations with 25(OH)D lower than 75 nmol/L (Salzer et al., 2012).  
Our study of reproductive age Finnish women is the largest longitudinal 
investigation to date to directly assess whether levels of vitamin D in healthy 
individuals predict the risk of MS occurrence. We included 1,092 women with MS 
diagnosed between 1983 and 2009 with at least 1 serum sample collected prior to 
date of MS diagnosis and a 3-fold control population from the cohort. Among the 
604 women with MS confirmed by medical record review, there was an average of 
9.5 years between first sample collection and recorded date of MS diagnosis, 
reducing reverse causation as an explanation of our results.  
Over half of the patients and controls had deficient serum 25(OH)D levels of <30 
nmol/L, and over one third of patients and controls had insufficient levels (30 to <50 
nmol/L). Less than 10 subjects among cases and controls, respectively, had 25(OH)D 
levels of ≥75 nmol/L. Given the low numbers of patients with sufficient and high 
25(OH)D levels, we were not able to assess MS risk associated with elevated vitamin 
D levels, but our findings are consistent with linear association of 25(OH)D and MS 
risk with decreasing risk as vitamin D levels rise. Our findings therefore complement 
previous prospective studies of similar design conducted in the US and Sweden that 
observed decreased MS risk in association to elevated levels of 25(OH)D (Munger 
et al., 2006; Salzer et al., 2012). 
In our study, deficient levels were mainly found in samples obtained prior to 
2004, which is the year when Finland formally recommended that pregnant women 
take vitamin D supplements. However, our findings of deficient and insufficient 
vitamin D levels during pregnancy in Finnish women support previous study 
observations (Viljakainen et al., 2010).  
Serum samples were collected from the mothers at ∼10-14 weeks gestation. 
Longitudinal studies of 25(OH)D in pregnant women and comparison of levels in 
pregnant and nonpregnant women suggest that 25(OH)D levels during the first 
trimester are reflective of non-pregnancy levels (More et al., 2003; Viljakainen et 
al., 2010). Since the majority of women in the FMC are Caucasian, our results may 
not be generalizable to females of other racial groups. We did not have specific 
information on demographic variables such as ethnicity or education level. Vitamin 
D deficiency may also increase the risk of MS in men, since previous findings 
support decreased MS risk with increasing 25(OH)D levels also in males (Munger 
et al. 2006; Salzer et al. 2012), but a separate study would be required to verify such 
speculations. 
Our findings directly support vitamin D deficiency during pregnancy as a risk 
factor for MS in both mothers and offspring and extend on previous prospective 
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study observations of 25(OH)D levels in young adults, suggesting that many 
individuals are exposed to an increased MS risk, which strengthens the rationale for 
broad public health interventions to prevent and correct deficient vitamin D levels. 
It is less clear what specific recommendation (if any) with regards to timing of 
vitamin D supplementation can be made. The timing of vitamin D effect may be as 
early as during the fetal period. A previous study has shown that 71% of women and 
15% of newborns are vitamin D-deficient during pregnancy although a mean total 
intake of vitamin D among mothers met current Nordic recommendations during the 
study period (Viljakainen et al. 2010). This observation is also supported by our 
study findings and justifies follow-up of vitamin D levels in vitamin D-deficient 
subjects and pregnant women after initiation of vitamin D supplementation. More 
research on the benefits, timing, optimal dose and serum target level of vitamin D 
supplementation on MS and comorbidity risk is needed but striving to achieve 
vitamin D sufficiency over the lifespan is likely to have multiple benefits. Since 
studies support vitamin D levels in adolescence as an important modulator of MS, 
vitamin D supplementation during this period, or earlier, might mitigate MS risk. 
6.1.2 Vitamin D levels, EBV and smoking 
We observed that offspring of mothers with high VCA IgG during pregnancy have 
an increased risk of MS that has not been previously observed. The risk of MS was 
2.5-fold increased among offspring of women with the highest levels (top quintile) 
versus the bottom quintile. No elevated risk for MS in the offspring was associated 
with maternal IgG levels against EBNA-1, EA-D or CMV. Among the women with 
increased pre-diagnostic EBNA-1 IgG levels we observed a 3-fold higher MS risk 
in the highest versus lowest quintile, a finding that is consistent with previous study 
results. These associations were not confounded or modified by maternal serum 
25(OH)D or cotinine levels, which has not been demonstrated previously. Women 
who developed MS had higher mean pre-onset serum cotinine levels than the 
controls, and those with cotinine levels indicative of smoking had a 45% increased 
risk of MS compared to non-smokers, which is consistent with previous study 
observations of smoking as a risk factor for MS. The results were not altered by 
EBNA-1 index value, 25(OH)D levels, parity or gravidity. The previous observed 
increased risk of MS among vitamin D-deficient women was not confounded by 
EBNA-1 IgG and cotinine, and in the offspring, the 2-fold risk of MS associated 
with maternal vitamin D deficiency persisted after adjustment for EBV IgG levels 
and cotinine.  
It has not previously been known whether in utero exposure to maternal EBV 
IgG Abs is associated with MS risk in the offspring, nor if there is an interaction with 
serum 25(OH)D and cotinine levels altering the risk. The association of EBV and 
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MS has been substantiated in multiple studies. Vitamin D status and many other 
factors continuously modulate the global MS risk, from pregnancy to MS triggering 
in adulthood and subsequent disease progression, whereas smoking is known to 
increase the risk of MS occurrence and disease progression in smoke-exposed 
subjects. These risk factors are also known to complexly interact with genes by 
reducing or adding to the risk of MS. HLA risk genes and IM seem to interact 
synergistically in increasing the risk of MS. An interaction between anti-EBV titers 
and the genes has been observed leading to a 16-fold higher risk for MS associated 
with abundance of HLA-DRB1*15 and absence of HLA-A*02 in combination with 
high EBNA 385-420 IgG titers compared to individuals who did not carry any of 
these factors (Sundqvist et al. 2012). An interaction between obesity and a history of 
IM during adolescence has been associated with an increased MS risk with an OR of 
approximately 14. This finding suggests that HLA risk alleles that encode molecules 
regulating T cell adaptive immunity might show common pathogenic pathways 
triggering MS when they interact with measures of EBV infection (Hedström et al., 
2015). A significant interaction between smoking and two genetic risk factors, 
carriage of human leucocyte antigen (HLA) DRB1*15 and absence of HLA A*02, 
has been described, suggesting that risk of MS disease associated with HLA 
genotypes may be strongly influenced by smoking (Anna Karin Hedström, 
Sundqvist, et al., 2011). 
In addition to evaluating a possible risk association between MS and EBV Abs 
during pregnancy affecting both mothers and offspring, we sought to examine 
whether our findings would be further confounded by maternal serum 25(OH)D and 
cotinine levels. We did not, however, evaluate Abs against CMV and possible impact 
on MS risk among the mothers. Only risk-association with EBNA1 was conducted 
since these Abs have been identified as a predictive marker among adults at the time 
of our study.  
Prior study observations suggest that smoking is an independent risk factor for 
MS. Adult tobacco smokers of both sexes run an increased risk of developing MS 
compared to never-smokers and there is a dose-response correlation between MS 
risk and cumulative dose of smoking, which remains up to 5 years after smoking 
cessation (Hedström et al., 2009). Serum cotinine has also been associated with a 1.5 
OR increase in MS risk (Salzer et al., 2013). Use of snuff over 15 years, on the other 
hand, decreases MS risk (Hedström et al., 2009). Exposure to SHS is associated with 
an increased MS risk in non-smokers (A. K. Hedström et al., 2011) and parental 
smoking has been associated with risk of MS in offspring (Mikaeloff et al., 2007), 
whereas no risk increase of early onset MS among offspring exposed to parental 
smoking during pregnancy has been demonstrated (Montgomery et al. 2008). 
Mechanisms linking smoking to MS risk are speculated to involve lung inflammation 
with a proinflammatory profile, as the interaction with MS risk HLA genes argues 
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for an action on adaptive immunity, possibly by activation of auto-aggressive cells 
resident in the lungs subsequently attacking the CNS. Possible interactions between 
lung irritative agents and HLA genes with regard to MS risk have been described to 
be consistent with class II allele-specific recognition of autoantigenic peptides in the 
lungs, resulting in organ specific inflammatory disease. For MS, absence of A*0201 
may result in autoreactive T cells persisting and launching an immune response 
against the self-antigen (Hedström et al., 2018). 
There are no previous studies on smoking prevalence among the Finnish MS 
population. Smoking habits and prevalence, demographics and perinatal and 
pregnancy outcomes among pregnant women in the FMC have been studied for the 
years 1987-2011 in 9,627 randomly selected pregnancies based on measured serum 
cotinine levels (≥4.73 ng/mL deemed high) and self-reported smoking status. Of the 
women, 7.7% undisclosed smoking but had high cotinine levels and 4.5% were 
inactive cigarette smokers, while 71.6% were non-smoker and 16.2% were active 
cigarette smokers. The prevalence of active cigarette smokers decreased from the 
mid-1990s onwards among women aged ≥30 years, presumably due to the ban on 
cigarette smoking in most workplaces (Männistö et al., 2016). In a US study from 
2006, smoking was not higher among MS patients than controls, whereas other and 
more recent studies have reported a higher prevalence of smoking among MS 
patients in Sweden, the USA and Norway (Nortvedt, Riise and Mæland, 2005; Friend 
et al., 2006; Turner et al., 2007; Hedström et al., 2009; Hedström, Olsson and 
Alfredsson, 2016). Smoking is underrepresented, but also underreported, among 
pregnant women, making cotinine levels a more reliable study tool for evaluation of 
tobacco exposure (Dietz et al., 2011; Jain, 2017). We did not have data on self-
reported smoking, neither for women nor offspring in our study cohort.  
Cotinine (C10H12N2O), a by-product of nicotine (C10H14N2) metabolism, is the 
most sensitive and specific biomarker for cigarette smoking and tobacco exposure 
widely used to distinguish smokers from non-smokers in epidemiologic studies 
(Jarvis et al., 1987; Benowitz et al., 2009). Serum cotinine levels do not distinguish 
smoking from other means of nicotine exposure, nor do they exclude simultaneous 
use of snuff and smoked tobacco that may have antagonistic effects on risk of 
developing MS (Hedström et al., 2013). Presumably, snuffing is rare in the FMC 
cohort and unlikely to exert a significant impact on the MS risk estimation (0-1% of 
Finnish women are snuffers according to THL tobacco statistics from 2017). The 
magnitude of SHS exposure has declined in recent years due to proportionally fewer 
smokers and more clean indoor air regulations. In Finland, since 1994, the legal age 
to buy tobacco products was raised from 16 to 18 years, and the indirect 
advertisement of tobacco products and cigarette smoking indoors at workplaces 
(excluding restaurants), in governmental buildings and in public transportation was 
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banned. In 2004, indoor smoking was banned in restaurants, as well. The public 
display of cigarette products at shops was banned in 2010 (Männistö et al., 2016). 
In our study cohort, we could not evaluate the number of mothers who ceased to 
smoke during early pregnancy (an estimate of 49.2% in the general Finnish 
population in 2017, but half as high in 2007) (THL Tobacco Statistics, 2017). 
Smoking during pregnancy is associated with adverse birth outcomes, such as low 
birth weight, pre-maturity, neonatal mortality, childhood respiratory illnesses and 
abnormal nervous tissue development (Vyhlidal et al., 2013). Breastfeeding has been 
associated with a decreased risk of MS in children in some studies (Conradi et al., 
2013; Ragnedda et al., 2015). Cotinine is secreted in breast milk, and milk cotinine 
is positively associated with cigarette consumption, as well as inversely associated 
with the time since the last cigarette (Jacob, Golmard and Berlin, 2015). Maternal 
exposure to tobacco while breastfeeding has not been associated with MS risk in 
offspring (Graves et al., 2017). In our study, we did not have data on breastfeeding, 
but given the previous study findings, offspring exposure to cotinine in milk is 
unlikely to have an impact on the results, while breast feeding regardless of cotinine 
levels may have had an impact on MS risk among offspring. Smoking cessation may 
have had an impact on MS risk in women not accounted for in this study, but given 
our study findings, this would not alter the MS risk association with EBV antibodies 
or 25(OH)D levels. 
Racial and ethnic differences in cigarette smoking and in the rate of metabolism 
of nicotine and cotinine have been described previously. At the same daily level of 
cigarette smoking, lower serum cotinine concentrations are observed in whites than 
in blacks (Wagenknecht et al., 1990; Caraballo et al., 1998; Benowitz et al., 2009). 
Since the majority of women in the FMC are Caucasian, our results may not be 
generalizable to females of other racial groups. However, results of previous studies 
in more diverse populations suggest that our findings can be extrapolated to Finnish 
men (DeLorenze et al., 2006; Levin et al., 2010) and possibly to other racial groups 
(A. K. Hedström et al., 2011; Langer-Gould et al., 2017). The cotinine cut points 
generally used are presumably highly applicable with the same reliability to the 
majority or all the subjects in our cohort of mainly Caucasian subjects.   
In our study, there are some limitations to consider. EBV IgG antibodies were 
measured in serum samples collected mainly during the first trimester of pregnancy 
(70% of the samples). As cotinine is a short-term biomarker of smoking, we cannot 
rule out residual confounding or misclassification of women who were past smokers 
or light smokers as non-smokers. We did not have information on other MS risk 
factors, including obesity in early life, HLA status, breastfeeding, and a variety of 
demographic variables, including ethnicity or education level for either the offspring 
or mothers, though previous studies suggest none of these are confounders of the 
EBV-MS association (Levin et al., 2005; Gianfrancesco et al., 2014). Because 
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breastfeeding is unlikely to be associated with maternal antibody levels in early 
pregnancy, differences in breast feeding behavior do not provide a plausible 
explanation for the higher MS risk among offspring of mothers with higher VCA 
IgG levels. 
6.1.3 EBV infection and risk of MS 
In our study, a novel finding was the 2.5-fold increased risk for MS among offspring 
of mothers with high EBV VCA IgG Abs during pregnancy. Our observation that 
high EBNA-1 IgG levels were associated with MS risk in Finnish mothers confirms 
previous reports of increasing IgG Ab titers against EBNA being associated with an 
increased risk of MS in healthy adults (Ascherio and Munger, 2016). The association 
of EBV and MS was first suggested over 40 years ago (Tourtellotte, 1971) and has 
been substantiated in multiple subsequent studies (Ascherio and Munger, 2010; 
Owens and Bennett, 2012). Virtually all (99%) MS patients are seropositive for EBV 
(Pakpoor, Pakpoor, et al., 2013), but EBV seropositivity is high (95%) also in non-
MS subjects (Luzuriaga and Sullivan, 2010). In our study, 98.3% of offspring case 
mothers and 97.8% of control mothers were positive for EBV infection. For the 
mother cases and controls, 99.3% and 97.7% respectively, were seropositive for 
EBV in their pre-onset samples, yielding a nearly 3.5-fold increased MS risk 
associated with EBV seropositivity. Maternal Ab titers were measured an average of 
9 years prior to their MS diagnosis, greatly reducing the probability of reverse 
causation.  
Primary infection with EBV is a strong risk factor for MS (Levin et al., 2010), 
and a history of IM more than doubles the risk of developing MS (Handel et al., 
2010). We did not have data on a history of IM (typically a manifestation of primary 
EBV infection during adolescence or young adulthood), neither for the mothers, nor 
for the offspring in the cohort. The strengths of our study include the utilization of a 
population-based cohort; the FMC includes 98% of all pregnancies in Finland since 
1983. Identifying MS cases via the nationwide hospital and prescription registries 
also minimized selection bias. The prospective nature of the study is a considerable 
strength, as exposure to maternal EBV IgG Abs necessarily occurred prior to the 
offspring developing MS. 
6.1.4 Could higher maternal EBV antibodies postpone the 
EBV infection in the offspring 
Primary infection with EBV is a strong risk factor for MS (Levin et al. 2010). In 
healthy adults, increasing IgG Ab titers against the EBNA have been associated with 
an increased MS risk (Ascherio and Munger, 2016). Increased Ab titers could be 
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speculated to be the consequence of a poor elimination of the pathogen through cell-
mediated immunity (analogous to observations in JC-virus carriage wherein high 
antibody titers show a poor control over viral replication) (Sundqvist et al., 2014).  
Since viral Abs, including those against EBV, are known to cross the placenta 
during pregnancy (Gotlieb-Stematsky et al., 1983), they may potentially delay the 
age at primary EBV infection in the child by conferring temporary protection. This 
could possibly alter the child’s immune response to EBV infection and thus MS risk. 
EBV has oncogenic properties increasing the risk of certain cancers, in particular 
among immunocompromised individuals. A prior FMC study showed an association 
between higher maternal VCA IgG Ab levels and increased risk of testicular cancer 
in their male offspring (Holl et al., 2008). Maternal EBV Abs may potentially affect 
the risk of other long-term diseases in offspring. One prior study found that among 
66 infants with maternal EBV IgG Abs at birth, 12% continued to have detectable 
Abs after 4 months, and half of these infants became infected between 20-24 months 
old while half remained uninfected by EBV through their second year (Chan et al., 
2001). In our FMC study on EBV and MS risk, we showed that maternal VCA IgG 
levels during pregnancy were associated with MS risk among offspring. A one 
standard deviation increase in maternal VCA IgG index value was associated with a 
34% increased MS risk in the offspring, and in quintile analyses, children of mothers 
in the highest quintile of VCA IgG index value had a 2-fold increased risk of MS 
occurrence. No association was observed with EBNA-1 IgG, EA-D IgG or CMV 
IgG index values. 
The biological mechanism behind this observation is uncertain. One possibility 
is that the child’s own immune response to a primary EBV infection is delayed if the 
offspring of mothers with high VCA IgG are exposed to higher maternal VCA IgG 
during pregnancy. One hypothesis is that an “older” child may be prone to a more 
aberrant immune response to primary EBV infection than a “younger” child once the 
maternal protection wanes, and this may predispose them to MS. An alternative 
explanatory hypothesis is that shared genetics (e.g. HLA haplotypes) between the 
mother and child influence their immune response to EBV such that the mother’s 
elevated VCA IgG levels may be an indicator of an elevated Ab response to EBV in 
the offspring.  
Although current study findings suggest an association, little is still known about 
how maternal Abs may influence the child’s immune response to EBV, and how this 
affects the risk of chronic diseases in the offspring. 
6.1.5 Potential for EBV vaccination 
EBV infection has been associated with morbid conditions such as MS and cancer. 
The absence of an anti-EBV drug might be partly explained by the difficulty in 
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diagnosing IM (long incubation time of 4-6 weeks), difficulty in achieving high 
antiviral concentrations in the oropharynx where the EBV is released at high titers, 
and the fact that symptoms and signs of the disease are not the consequence of viral 
replication but the immunological response to circulating EBV-infected B cells and 
infiltrating tissues of different organs. Potential antiviral therapeutics, including 
vaccines, to treat or prevent EBV related diseases are under evaluation, but are still 
not approved in the clinic for treatment of EBV infections (Andrei, Trompet and 
Snoeck, 2019).  
There are few studies examining whether maternal EBV Abs are associated with 
longer-term chronic diseases in the offspring. In prior FMC studies, higher maternal 
VCA IgG Ab levels showed an association with a 2.5-fold increased risk of testicular 
cancer among male offspring (Holl et al. 2008), whereas maternal EBV Abs were 
not associated with acute lymphoblastic leukemia in the offspring (Tedeschi et al. 
2009). It is possible that a future EBV vaccine with excellent coverage providing 
lifelong protection against EBV infection could prevent chronic diseases such as MS 
and cancers, presumably if targeted at a very early age. This kind of vaccine would 
hold the potential of being beneficial in subjects genetically susceptible to MS.  
However, EBV prevention is hard to achieve, since a safe and efficient vaccine 
is difficult to create. A vaccine with only partial efficacy in prevention of this large 
group of highly pertinent herpesvirus that latently hides in circulating B lymphocytes 
is accompanied with risks. Even if EBV seems to be critically involved in MS 
development, a future EBV vaccine of modest effectiveness might only postpone the 
time of primary EBV infection and thus potentially increase the MS risk, since EBV 
infection in adolescence appears to be associated with a higher risk of developing 
MS. Treatment and prevention of chronic diseases associated with the globally 
highly abundant EBV virus that is well adapted to coexistence with its human host, 
causing no apparent disease in the vast majority of individuals with normal 
immunity, still calls for rigorous research clarifying the role of EBV in MS. Means 
to identify target groups that could benefit from a vaccine would need to be 
developed, and extensive research is warranted on how and when a possible vaccine 
should be targeted and timed to prevent the development of MS without 
compromising safety. 
6.2 Effect of vitamin D supplementation on MRI 
activity and clinical outcomes on fingolimod 
therapy 
In our 24 months follow-up study on efficacy and safety outcomes in vitamin D 
supplement users among RRMS patients in the pivotal fingolimod phase 3 trials, we 
showed that vitamin D is safe, and vitamin D ´daily users´ had significantly better 
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MRI outcomes compared to ´non-users´. Among daily users a higher proportion of 
patients were free of new/enlarging T2 lesions compared to non-users. The mean 
number of MRI lesions was lower, and the proportion of patients free of Gd-
enhancing lesions was higher in daily users. PBVC was significantly lower at month 
12 and remained non-significantly lower at month 24 for the daily vitamin D users 
compared to non-users. The incidence of depression as an AE was lower among daily 
vitamin D supplement users (5.5%) compared to non-users (11.9%), although this 
finding did not reach statistical significance. Other AEs (incidence of infections) 
were equally frequent in the groups, supporting previous findings of vitamin D 
safety. The clinical outcome measures EDSS change from baseline, ARR and 
proportion of patients with relapses were similar across the vitamin D user groups.  
The effect of vitamin D in MS patients treated with fingolimod has not been 
studied previously, and we found only one previous study assessing the effect of 
serum vitamin D levels on MS activity by DMT class including fingolimod, which 
showed a reduction in new inflammatory events and in relapses alone per 25(OH)D 
tertile increase among patients treated with fingolimod (Rotstein, Healy, Malik, 
Carruthers, et al., 2015). Studies on beneficial effects of vitamin D supplementation 
in established MS have been controversial, but previous studies on vitamin D 
supplementation as an add-on treatment to IFN have yielded some positive results. 
In a phase 2 placebo-controlled randomized trial with vitamin D as an add-on therapy 
to IFN-beta, beneficial effect was observed on MRI outcomes (significantly less Gd-
enhancing T1 lesions), but not on relapses or EDSS progression for patients 
randomized to receive vitamin D at a dose of 20,000 IU/week (Åivo, Lindsröm and 
Soilu-Hänninen, 2012). A large vitamin D add-on to IFN-beta trial, the SOLAR 
study, met the primary MRI endpoints, and showed a 30% reduction in relapse rate, 
but the efficacy of vitamin D on relapses and other clinical endpoints was not 
statistically significant (Grimaldi et al., 2012). In the Benefit trial, low serum 
25(OH)D levels were associated with worse clinical and MRI outcomes in MS 
patients treated with IFN-beta 1b (Ascherio et al., 2014). The BEYOND-trial, in 
which a higher dose of 500 ug was compared to the standard dose (250 ug) of IFN-
beta 1b in 1482 patients, higher 25(OH)D levels were associated with lower rates of 
MS activity observed on MRI such that a 50 nmol/L increase in serum 25(OH)D 
levels was associated with a 30% lower rate of new lesions and the lowest rate of 
new lesions was observed among patients with 25(OH)D levels greater than 100 
nmol/L. Results for brain atrophy and clinical progression were equivocal 
(Fitzgerald et al., 2015). There is less evidence of vitamin D effect as an add-on to 
other first line DMTs than IFN and for second line DMTs in particular (James et al., 
2013; Berezowska, Coe and Dawes, 2019). It has been suggested that IFNs and 
vitamin D may have synergistic effect and observations of vitamin D efficacy in MS 
patients using IFN-beta would therefore not be generalizable to other DMTs (Stewart 
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et al., 2012). In support of this, the same study that showed beneficial effect of 
vitamin D serum levels on MS activity in the DMT subgroups for fingolimod (77 
patients) and IFN-beta, did not find any effect of vitamin D in the subgroup treated 
with GA (Rotstein, Healy, Malik, Carruthers, et al., 2015). The VIDAMS trial is 
assessing the efficacy of vitamin D as an add-on to GA and will hopefully provide 
more conclusive information (Bhargava et al., 2014).  
A recent publication has showed that in patients treated with fingolimod, those 
with the highest baseline 25(OH)D levels had a significantly lower number of active 
lesions at baseline MRI and the same effect, although weaker, was observed also at 
a 2-year follow-up when adjusting for baseline disease activity. No linear correlation 
between baseline 25(OH)D levels and ARR or time to first relapse was found, but 
patients  with vitamin D levels of ≥100 nmol/L showed a lower number of Gd-
enhancing and combined unique activity (CUA) lesions at baseline compared to 
patients with the lowest 25(OH)D levels (< 50 nmol/L, p-value <0.05), as well as 
fewer CUA lesions at 2-year follow-up also when accounting for baseline disease 
activity level (Ferré et al., 2018). MRI is highly sensitive for detecting disease 
activity and new T2 and Gd enhancing T1 lesions may occur sub-clinically. These 
are seen more frequently than clinical relapses  (Barkhof et al., 1992; Barkhof, 2002) 
and since there are previous observations of a strong correlation between therapy 
effect on active lesions and relapse rate (Sormani et al., 2011), MRI may serve as a 
surrogate marker for relapses.  
In a study that assessed the mechanistic rationale that may explain potential 
clinical effects of vitamin D in MS, vitamin D was found to regulate expression 
dynamics of a large gene-gene interaction system which primarily regulates immune 
modulatory processes modulating MS activity. Targets of IFN-beta and a regulator 
of sphingosine-1-phosphate bioavailability were found among the vitamin D 
regulated genes. More specifically, vitamin D regulated SGPP1, a gene that encodes 
for an enzyme that catalyzes the degradation of S1P. Degradation of the S1P receptor 
decreases receptor availability to lymphocytes and thus acts in the same direction as 
fingolimod, providing a potential beneficial mechanism of action of vitamin D 
alongside fingolimod (Munger et al., 2014). 
Vitamin D supplementation may be beneficial in MS comorbid conditions, such 
as depression (Shaffer et al., 2014), diabetes mellitus (Nakashima et al., 2016), 
infections (Hewison, 2011), respiratory tract infections in particular (Bergman et al., 
2013; Martineau et al., 2019) and cancer (Bjelakovic et al., 2014). Potentials for 
fingolimod and vitamin D in cancer treatment have been described. Fingolimod 
reverses the inhibitory effect of S1P on NK cell lysis of tumor target cells or dendritic 
cells (DCs) attributed to by binding S1P1 on NK cell surface (Rolin et al., 2010; 
Pyne and Pyne, 2013). Vitamin D3 activates NK cells to kill melanoma cells, an 
activity related to induction of apoptosis (Lee et al., 2011). In vitro studies for 
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fingolimod, the biologically active D3 metabolite and calcitripotriol, showed that 
they augment IL-2-activated NK cell lysis of certain tumor cell lines (K562 and 
RAJI), as well as immature and mature DCs, observations that may be potentially 
used for treating MS or other autoimmune diseases in the future (Al-Jaderi and 
Maghazachi, 2013). Since fingolimod has an immunosuppressive effect due to the 
reduction of circulating lymphocytes, intrinsic cancer surveillance may also be 
impaired. Fingolimod AEs include increased rates of viral infections such as VZV, 
and also chronic, treatment refractory human papilloma virus (HPV) warts have been 
described. Thus, risk of cancers associated with HPV may be increased in fingolimod 
treated patients (Triplett et al., 2018). 
Depression is the most common co-morbidity with the greatest impact on quality 
of life in people with MS (D'Alisa et al., 2006; Taylor et al., 2014). An inverse 
association between serum 25(OH)D levels and depression risk has been shown in a 
meta-analysis comprising 11 cross-sectional studies in over 400,000 mostly elderly 
non-MS patients (Ju, Lee and Jeong, 2013), whereas an association of depression  
with vitamin D intake and serum 25(OH)D levels is less established in MS patients 
(Taylor et al. 2015). One objective of our study was to assess the reported depression 
among vitamin D supplement users and non-users. Depression as an AE was lower 
among the fingolimod treated patients who were vitamin D users compared to non-
users. 
A major caveat of our study was that we did not know serum levels of 25(OH)D 
in the study subjects. Confounding factors, such as smoking (a risk factor for worse 
clinical outcomes in MS), genetic factors, ethnicity, socioeconomic status and 
differences in lifestyle, precise latitude and previous DMT were not evaluated. Age, 
gender, BMI, MS duration since diagnosis, and EDSS and relapse rate at baseline, 
were included in the baseline characters. BMI and T2 lesion volume were 
significantly lower for baseline characters in the vitamin D daily user subgroup 
compared to non-users. Some of these confounding factors may have altered our 
results and our findings might not be generalizable to all ethnic groups. We did not 
evaluate cancer incidence in this short-term follow-up. Vitamin D supplementation 
RCTs are mandatory for future vitamin D recommendations in MS, and due to 
vitamin safety and potential mechanisms of action in demyelinating disease (Lucas, 
A-L Ponsonby, et al., 2011), it could in particular be interesting in a target group of 
RIS subjects (a patient group known to be affected with subclinical symptoms of 
cognitive impairment), and since there is still no evidence-based support for benefit 
or safety for initiation of DMTs used for MS. In future Phase 3 studies, considering 
the accumulated evidence pointing to the benefits of vitamin D with low risks and 
costs, it may become difficult to randomize patients to not receive any vitamin D 
supplementation in a placebo arm.  
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6.3 Environmental factors and risk of cancer 
among MS patients 
In this nested case-control study we assessed cancer risk among Finnish MS patients 
in the hospital district of Southwest Finland during the DMT era from 2004 to 2013. 
We confirmed similar findings as in the pre-DMT era for the same population 
(Sumelahti, Pukkala and Hakama, 2004). The overall cancer risk in the MS cohort 
did not significantly differ from the controls in the same hospital district. The age at 
BC diagnosis was statistically significantly higher among MS patients than controls, 
but BC risk did not significantly differ between the groups. Numbers in other cancer 
subgroups were small, preventing us from drawing further conclusions.  
Previous studies on cancer risk among the MS population have been inconsistent, 
which might reflect the variability of different populations, time of analysis and 
variability in the MS pharmacotherapies used.  
In Finland, the most common cancer in women is BC and in men prostate cancer 
(Pukkala and Rautalahti, 2013; The Finnish Cancer Registry, 2019). Risk for prostate 
cancer in our MS cohort was also decreased compared to controls and is in line with 
a majority of previous study observations (Kyritsis, Boussios and Pavlidis, 2016), 
although numbers in our study were small. 
Our findings of higher age at BC diagnosis among MS patients compared to 
controls could speculatively be linked to a protective effect of a more active immune 
system. An alternative explanation is a negative surveillance bias caused by neglect 
of the patients’ symptoms and complaints other than the MS-related ones (there was 
no data on the BC tumor size at diagnosis to support this speculation), or reluctance 
of patients to attend the screening mammography in addition to the follow-up burden 
caused by frequent MS clinic visits. The difference at age of BC was as long as six 
years, making the latter explanation less likely.  
Increased BC risk has been associated with smoking in several recent studies 
(Olson et al., 2005; Cui, Miller and Rohan, 2006; Nagata et al., 2006; Ha et al., 2007; 
Xue et al., 2011; Deroo, Cummings and Mueller, 2011; Luo et al., 2011; Bjerkaas et 
al., 2013; Rosenberg et al., 2013; Gaudet et al., 2013; Dossus et al., 2014; Jones et 
al., 2017). Data on smoking was scarce, but 44.5% of the BC patients in our MS 
cohort were non-smokers and for 50% data was not available. The percentage of 
smokers (5.6%) was not lower than reported in the elder nationwide Finnish female 
population (5%), but lower than for smoking Finnish females aged 20-64 years 
(13%) (THL tobacco statistics 2017). The reported low rate of smoking among MS 
BC patients could contribute to the slightly lower BC rate as well as the higher age 
at diagnosis. The MS patients in our cohort had mostly used platform MS therapies, 
and BC patients in our MS cohort received only IFN or GA, but the patient numbers 
were too small to draw any conclusion on the possible impact of DMTs on cancer 
risk in our cohort. 
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In the ocrelizumab Phase 3 studies, an equal or increased risk of BC among the 
RRMS population and a signal for an increased risk among the PPMS patients were 
observed (Hauser et al., 2017; Montalban et al., 2017). If the non-significant trend 
of a lower baseline BC risk among MS patients observed in our study is true, then 
even an equal risk for BC among patients receiving ocrelizumab, as compared to IFN 
and placebo, could suggest that there is an increased BC risk associated with 
ocrelizumab exposure. Evaluation of cancer risk in the MS population remains 
relevant in the era of new and emerging DMTs and in the evaluation and 
management of their potential long-term safety profiles. 
We found trends of increased risk for brain cancer, oral cavity cancer, renal 
cancer, lung cancer, colon cancer in our MS cohort. The increased risk of brain 
cancer, in line with observations prior to the DMT era (Sumelahti et al. 2004), may 
reflect a surveillance bias from a more frequent routine MRI screening of MS 
patients (Kingwell et al 2012). Patient numbers in cancer subgroups that displayed 
increased risk in our MS cohort were very small. The increased rate of renal and 
colon cancer in our MS cohort might reflect a more common referral policy to 
urologists and gastroenterologists for MS-related symptoms and dysfunctions. 
Increased risk for oral cavity cancer, lung and thyroid cancer could reflect a shared 
risk factor for MS and cancer such as smoking, or possibly reflect a more frequent 
routine of X-ray imaging related to disease exacerbations and screenings for 
underlying infections. Among the small number of MS patients diagnosed with brain 
cancer, renal cancer, lung cancer and oral cancer in our cohort we found that 40% 
were smokers, 30% non-smokers and for 30% data was not available. This 
percentage of smokers was higher than the percentage of smokers in the Finnish 
population in general, and it could therefore be speculated that smoking rather than 
MS itself had an impact on the increased rates of these cancer subtypes (except for 
brain cancer, which has not been associated with smoking), although data on 
smoking for the control cohort was not available.  
Our MS cohort was reasonably large, representing about 15% of the total Finnish 
MS population, but for the detection of rare and slowly developing diseases such as 
cancers, large population-based studies spanning decades of follow-up are 
necessary. The number of cancer patients in the MS cohort was small (n = 61) and 
for specific cancer subgroups even smaller, making statistical conclusions uncertain. 
Data on ethnicity was not available, but the southwestern Finnish population is 
mainly Caucasian and study findings may not apply to other ethnicities and 
geographical areas. Our results were not confounded by complicated histories of 
different DMTs, but the numbers were also too small to make any conclusion on 
impact of DMTs on cancer risk possible. Another caveat of our study was also the 
scarce information on possible confounding factors that may alter the risk of both 
MS and cancer, such as parity, smoking, vitamin D status, hormonal replacement 
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therapy and other medications, alcohol abuse, BMI, family history of MS and 
cancers and socioeconomic status.  
Cancer deaths are overrepresented in at least part of the Finnish MS population 
(Sumelahti et al., 2002), which might be attributable to the longer life expectancy of 
MS patients. Cancer diagnosis in our cohort was preceded by MS diagnosis in the 
majority of our cohort, which is in line with the known fact that MS is predominantly 
a disease of young adults, whereas the risk of cancer occurrence increases over time. 
Risk factors such as obesity, low parity and smoking need to be documented and 
taken into account in population studies. There are studies suggesting a possible anti-
cancer activity of TFR on aggressive subtype tripe-negative BC and non-small cell 
lung cancer (Huang et al., 2015; Jiang et al., 2018). DMTs with possible cancer 
protective properties, including fingolimod, also warrant further studies on this 
potential. 
 
 81 
7 Conclusions 
The purpose of this thesis was to investigate whether pre-diagnostic serum 25(OH)D 
levels during pregnancy are associated with later MS risk in the mother and her 
offspring. We investigated whether maternal serum EBV antibodies during 
pregnancy are likewise associated with MS risk in either mother or child, and 
whether there is an association independent of serum 25(OH)D levels and cotinine. 
Furthermore, we performed datamining and post hoc analysis of pooled data from 
the Phase 3 FREEDOMS trials to assess whether vitamin D supplementation is 
beneficial and safe combined with fingolimod in the treatment of RRMS patients. 
We also updated data on cancer risk among MS patients in southwestern Finland in 
the era of DMTs, compared to controls from the same hospital district. The 
conclusions based on the results presented in this thesis are as follows. 
I. We showed that maternal vitamin D deficiency during early pregnancy 
doubled the risk of MS risk in the offspring. Correcting the mother’s vitamin 
D deficiency prior to or during pregnancy is likely to have a beneficial effect 
on the risk of MS in her child. 
We further showed that maternal vitamin D deficiency during pregnancy 
was associated with a 43% higher risk of MS when compared to women with 
sufficient levels in the cohort, whereas a MS risk reduction of 39% was 
associated with a 50 nmol/L increase in 25(OH)D levels. Vitamin D-
deficient women with multiple pre-diagnostic samples available had a 2-fold 
higher MS risk as compared to women with sufficient 25(OH)D levels. The 
results support vitamin D deficiency as a risk factor for MS and strengthen 
the rationale for broad public health interventions to improve vitamin D 
levels, especially in pregnant women and subjects with manifest MS or 
disease susceptibility. Correcting vitamin D deficiency and insufficiency to 
sufficient levels is likely to be safe, cost-effective and to have multiple 
potential health benefits.  
II. Women with levels of cotinine >25 ng/ml (smokers) had a 45% increased 
risk of MS as compared to women with cotinine levels of <10 ng/ml (non-
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smokers) confirming smoking as a risk factor for MS also in the Finnish 
population. 
III. We observed that offspring of mothers with high Epstein-Barr VCA IgG 
during pregnancy have an increased risk of MS that has not been previously 
observed. The risk of MS was 2.5-fold increased among offspring of women 
with the highest levels (top quintile) versus the bottom quintile. No elevated 
risk for MS in the offspring was associated with maternal IgG levels against 
EBNA-1, EA-D or cytomegalovirus. Among the women with increased pre-
diagnostic EBNA-1 IgG levels, we observed a 3-fold higher MS risk in the 
highest versus lowest quintile, a finding that is consistent with previous 
study results. These associations were not confounded or modified by 
maternal serum 25(OH)D or cotinine levels, which has not been 
demonstrated previously.  
IV. We found that Vitamin D supplementation as an add-on therapy to 
fingolimod for MS was safe in the FREEDOMS study population pool, 
showing beneficial outcomes on MRI T2 lesions and PBVC of statistical 
significance in vitamin D users compared to non-users during a 2-year 
follow-up. Depression as an AE was non-significantly lower among 
supplement users compared to non-users. These findings support a 
beneficial role of D vitamin supplementation in RRMS patients treated with 
fingolimod. Supplementation may also be beneficial in depressive co-
morbidity. 
V. We observed that the overall risk of cancer among MS patients in 
southwestern Finland was equal to controls from the same hospital district. 
Age at BC diagnosis was significantly higher and there was a slight trend of 
lower BC risk among MS patients compared to the control patients. Impact 
of smoking and DMTs on cancer risk could not be evaluated due to small 
patient numbers in cancer subgroups and incomplete data on lifestyle 
factors, including BMI, smoking and vitamin D supplementation. 
As an overall conclusion and recommendation based on our results, we propose 
correcting vitamin D deficiency during pregnancy at the population level and in 
particular in pregnancy planning for MS patients. In all MS patients, we recommend 
analyzing 25(OH)D levels after MS diagnosis and initiation of vitamin D 
supplementation targeting sufficient levels. Based on previous study findings 
regarding safety and detectable effects on MS disease activity in the Finnish 
population, a vitamin D dose of 50 to 100 ug/day, targeting serum 25(OH)D levels 
above 100 nmol/L could be beneficial for MS patients. Serum levels should 
preferably be re-evaluated after initiation of vitamin D supplementation to confirm 
compliance and achievement of targeted levels. Correcting for vitamin D deficiency 
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is likely to be beneficial in both pregnant women and their offspring also from a 
broader health perspective. Maternity care units could be suitable for screening, 
initiation of supplementation as well as for follow-up of vitamin D-deficient 
pregnant women in this aspect. Elevated maternal viral Abs in serum may traverse 
the placenta and protect the child from early EBV infection. This could possibly 
delay primary EBV infection in the child such that MS risk is altered. Rigorous future 
studies are needed before a potential EBV vaccine could be targeted at MS 
prevention. Whether or not smoking during pregnancy affects the long-time risk of 
offspring developing MS, as evaluated by exposure to elevated cotinine levels in 
utero should be further assessed. Future studies clarifying whether different forms of 
lung irritation, such as air pollution triggers, contribute to MS occurrence, as well as 
studies clarifying the mechanisms of the smoking related MS risk are warranted. 
Furthermore, given the vitamin D supplementation safety profile, MS patients 
treated with fingolimod could probably benefit from 25(OH)D levels above those 
currently considered to be sufficient for bone health, also if a causal effect has not 
yet been shown. Our findings suggest a possible beneficial impact of vitamin D 
supplementation, not only in MS disease activity, but also on depression and 
consequently, quality of life. 
MS patients in southwestern Finland do not have an increased, nor decreased, 
risk for cancers compared to non-MS patients. Further population-based studies 
spanning longer follow-up periods are needed to confirm the MS patient’s cancer 
risk during the era of evolving MS treatments. Risk factors shared by MS and other 
comorbidities, such as cancer, remain highly relevant, and smoking should be 
actively screened for and cessation encouraged for the population in general and MS 
patients in particular.  
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